



RESEARCH OPPORTUNITIES ALERT!



Issue 18: Volume 1b
RESEARCH GRANTS FROM NIH
(QUARTER: JULY - SEPTEMBER, 2014)

A Compilation by the
Research Services Unit
Office of Research, Innovation and Development (ORID)

June 2014

TABLE OF CONTENTS

Pilot And Feasibility Clinical Research Grants In Arthritis And Musculoskeletal And Skin Diseases (R21)	5
MHealth Tools For Individuals With Chronic Conditions To Promote Effective Patient-Provider Communication, Adherence To Treatment And Self-Management (R01)	6
Core Infrastructure And Methodological Research For Cancer Epidemiology Cohorts (U01)	7
Prevention Innovation Programme (R01).....	8
Imaging And Biomarkers For Early Cancer Detection (R01).....	8
Detection Of Pathogen-Induced Cancer (Dpic) (R01).....	9
Nei Audacious Goal Initiative: Addressing Technical Needs And Opportunities For Imaging The Visual System (U01)	10
Integrated Preclinical/Clinical Aids Vaccine Development Programme (U19)	11
Innovation For Hiv Vaccine Discovery (R01)	12
Targeting Latently Infected Cells Without Reactivation (R01).....	13
Epidemiology And Prevention In Alcohol Research (R21).....	14
Small Grants Program For Cancer Epidemiology (R03).....	15
Limited Competition: Planning Grant For Fogarty Hiv Research Training Programme For Low- And Middle-Income Country Institutions (D71).....	16
Limited Competition: Fogarty Hiv Research Training Programme For Low- And Middle-Income Country Institutions (D43).....	17
Chronic Wounds: Advancing The Science From Prevention To Healing (R01)	18
Research In Latent Tuberculosis Infection In The Setting Of Hiv Co-Infection (R01)	19
Grand Opportunity In Medications Development For Substance-Use Disorders (U01).....	20
Strategic Alliances For Medications Development To Treat Substance Use Disorders (R01)	21
Avant-Garde Award Programme For Hiv/ Aids And Drug Use Research (Dp1).....	22
Advancing Exceptional Research On Hiv/ Aids And Substance Abuse (R01)	22
High Throughput Screening To Discover Chemical Probes (R03)	24
Multidisciplinary Studies Of Hiv/ Aids And Ageing (R21).....	25
Multidisciplinary Studies Of Hiv/ Aids And Ageing (R01).....	26
Multidisciplinary Studies Of Hiv/ Aids And Ageing (R03).....	27

Translational Research In Paediatric And Obstetric Pharmacology (R03)	28
Translational Research In Paediatric And Obstetric Pharmacology (R01)	29
Translational Research In Paediatric And Obstetric Pharmacology (R21)	30
Cutting-Edge Basic Research Awards (R21)	31
International Research In Infectious Diseases (R01): Aids-Related	32
Targeting Co-Dependent Molecular Pathways In Oral Cancer (U01).....	33
Small Grants Programme For Cancer Research (R03): Aids-Related	35
Nci Exploratory/Developmental Research Grant Programme (R21): Aids-Related	36
Aids-Science Track Award For Research Transition (R03)	37
Small Grants For New Investigators To Promote Diversity In Health-Related Research (R03): Aids-Related	38
Synthetic Psychoactive Drugs And Strategic Approaches To Counteract Their Deleterious Effects (R03): Aids-Related	39
Synthetic Psychoactive Drugs And Strategic Approaches To Counteract Their Deleterious Effects (R21): Aids-Related	40
Family-Centred Self-Management Of Chronic Conditions (R21): Aids-Related	41
Alcohol-Induced Effects On Tissue Injury And Repair (R21): Aids-Related	41
Prevention And Treatment Of Substance Using Populations With Or At Risk For Hepatitis C Virus (R34): Aids-Related	42
Prevention And Treatment Of Substance Using Populations With Or At Risk For Hepatitis C Virus (R21): Aids-Related	43
Neuroimmune Mechanisms Of Alcohol-Related Disorders (R21): Aids-Related	44
Community Partnerships To Advance Research (R21): Aids-Related	45
Establishing Behavioural And Social Measures For Causal Pathway Research In Dental, Oral And Craniofacial Health (R21): Aids-Related	46
Translational Research To Help Older Adults Maintain Their Health And Independence In The Community (R21): Aids-Related.....	47
Effects Of Cannabis Use And Cannabinoids On The Developing Brain (R21): Aids-Related	48
Effects Of Cannabis Use And Cannabinoids On The Developing Brain (R03): Aids-Related	49
Nida Research Education Programme For Clinical Researchers And Clinicians (R25): Aids- Related	50
Nhlbi Systems Biology Collaborations (R01)	51
Biophysical And Biomechanical Aspects Of Embryonic Development (R01)	52

Biophysical And Biomechanical Aspects Of Embryonic Development (R21) 53

Early-Stage Innovative Molecular Analysis Technology Development For Cancer Research
(R21) 54

Design And Development Of Novel Technologies For Healthy Independent Living (R21) 55

Technologies For Healthy Independent Living (R01)..... 56

Genetic And Genomic Analysis Of Xenopus (R01)..... 56

Genetic And Genomic Analysis Of Xenopus (R21)..... 57

JULY 2014

P ILOT AND FEASIBILITY CLINICAL RESEARCH GRANTS IN ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES (R21)

NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

Description:

The National Institute of Arthritis and Musculoskeletal and Skin Diseases invites applications for its pilot and feasibility clinical research grants in arthritis and musculoskeletal and skin diseases (R21). This R21 funding opportunity announcement supports clinical research related to the prevention or treatment of arthritis and musculoskeletal and skin diseases, conditions or injuries. The programme is designed to allow initiation of exploratory, short-term clinical studies, so that new ideas may be investigated without stringent requirements for preliminary data. The short-term studies should focus on research questions that are likely to gather critical preliminary data in support of a future, planned clinical trial. They can include testing new or prevention strategies, a new intervention, or unique combinations of therapies. A high priority is the use of such studies to help stimulate the translation of promising research developments from the laboratory into clinical practice.

Direct costs are limited to US\$275,000 over a two-year period, with no more than US\$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit or nonprofit organisations and public or private institutions may apply.

Ref: PAR-14-060 (replaces PAR-10-282).

Closing date: 01 Jul 14

Deadline information: Applications due by 5pm local time of applicant organisation.

Deadlines on: 7 April 2014, 1 July 2014, 3 November 2014.

Posted date: 07 Jan 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-060.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true;jsessionId=S4GHSLhfY1p3bPg2pqZcnZy1IYsnM9fvZCnpHMGFd2Xvvdky3QM3?oppNum=PAR-14-060>

Eligibility profile

Country of applicant institution: Any

Disciplines

Treatment, Medical, Rheumatic Diseases, Arthritis, Dermatology, Muscle Disorders, Clinical Laboratory Science, Musculoskeletal System, Rheumatology, Skeletal Diseases, Clinical Laboratory Sciences (RAE Unit 1), Skin Diseases, Disease Prevention

Contact Details

NIAMS

One Democracy Plaza
6701 Democracy Boulevard
Bethesda, MD 20892
Tel: +1 301 594 1963
Email: witterj@mail.nih.gov

MHEALTH TOOLS FOR INDIVIDUALS WITH CHRONIC CONDITIONS TO PROMOTE EFFECTIVE PATIENT-PROVIDER COMMUNICATION, ADHERENCE TO TREATMENT AND SELF-MANAGEMENT (R01)

NIH: National Institute of Nursing Research

Description:

A total of two institutes and offices of the NIH invite applications for their mHealth tools for individuals with chronic conditions to promote effective patient-provider communication, adherence to treatment and self-management (R01) grants. The purpose of this R01 funding opportunity announcement is to stimulate research utilising mobile health (mHealth) tools aimed at the improvement of effective patient-provider communication, adherence to treatment and self-management of chronic diseases in underserved populations.

This funding opportunity announcement will utilise the NIH research project grant R01 mechanism and runs in parallel with another FOA of identical scientific scope: PA-14-181 that solicits applications under the exploratory/developmental grant (R21) funding mechanism. Application budgets are not limited, but need to reflect actual needs of the proposed project. The total project period is a maximum of five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Ref: PA-14-180 (Reissue of PA-11-330).

Closing date: 05 Jul 14

Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 May 2017.

Posted date: 23 Apr 14

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award amount min: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-180.html>

Application form:

Eligibility profile

Country of applicant institution: Any

Disciplines

Information & Communication Systems, Cost-effectiveness, Interventions & Treatment, Patient Care & Education, Rural Health, Intervention, Agents for (Health & Safety & Medical), Diagnosis, Medical, Technology Assessment & Transfer & Outreach (Health & Medical), Mobile Wireless Environments, Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Computer Science (RAE Unit 25), Electrical and Electronic Engineering (RAE Unit 29), Community-based Clinical Subjects, Hospital-based Clinical Subject, Screening For Diseases, Chronic Diseases

Contact Details

Tel: +1 301 594 5971

Email: mccloskd@mail.nih.gov

CORE INFRASTRUCTURE AND METHODOLOGICAL RESEARCH FOR CANCER EPIDEMIOLOGY COHORTS (U01) *NIH: National Cancer Institute*

Description:

The National Cancer Institute invites applications for its core infrastructure and methodological research for cancer epidemiology cohorts call (U01). This U01 funding opportunity announcement provides targeted infrastructure support for the core functions of cancer epidemiology cohorts and methodological research. This infrastructure can support existing or new CECs. This funding opportunity announcement will support core functions for CECs currently funded through other grant mechanisms by the epidemiology and genetics programme and other components of the division of cancer control and population sciences at the National Cancer Institute.

US and foreign public and private non-profit organisations and for-profit organisations may apply.

Applications budgets are not limited, but must reflect the actual needs of the project. The maximum project duration is five years.

Ref: PAR-14-160 (replaces PAR-11-167).

Closing date: 08 Jul 14

Deadline information: Applications due by 5pm proposer's local time. Deadlines on: 8 July 2014, 10 November 2014, 11 March 2015, 8 July 2015, 10 November 2015, 11 March 2016, 8 July 2016, 10 November 2016, 10 March 2017.

Posted date: 20 Mar 14

Award type: Networking/collaboration, Research centres, Directed grants to institutions, research groups etc

Award amount max: -

Award amount min: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-160.html>

Application form:

<http://www.grants.gov/web/grants/applicant/download-application-package.html#download=true&oppNum=PAR-14-160>

Eligibility profile

Country of applicant institution: Any

Disciplines

Clinical Laboratory Sciences (RAE Unit 1),
Cancer Biology, Clinical Laboratory Science,
Epidemiology, Cancer & Carcinogenesis

Contact Details

Epidemiology and Genomics Research
Programme

Division of Cancer Control and Population
Sciences

NCI

9609 Medical Center Drive, 4E130

Rockville, MD 20850

Tel: +1 240 276 6748

Email: seminard@mail.nih.gov

PREVENTION INNOVATION PROGRAMME (R01) *NIH: National Institute of Allergy and Infectious Diseases*

Description:

The National Institute of Allergy and Infectious Diseases invites applications for its preclinical innovation programme (R01). This R01 call supports high risk and innovative research and development efforts designed to establish and maintain a sustainable pipeline to prevent HIV acquisition or transmission. The call will focus on novel and underexplored nBP candidates, delivery strategies, studies of the impact of nBP prevention strategies on genital and gastrointestinal mucosa function and emerging technologies that support microbicides, pre-exposure prophylaxis and multipurpose prevention technologies.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.

NIAID will commit US\$2.4 million to funding four to six awards in fiscal year 2015. Applicants may request up to US\$400,000 in direct costs per year, over a maximum of four years.

Ref: RFA-AI-13-059 (replaces RFA-AI-13-008).

Closing date: 10 Jul 14

Deadline information: Applications due by 5pm proposer's local time.

Posted date: 21 Feb 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$1,600,000

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-13-059.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=RFA-AI-13-059>

Eligibility profile

Country of applicant institution: Any

Disciplines

Transmission of HIV/AIDS, Disease Prevention, Community-based Clinical Subjects (RAE Unit 2), Screening of Drugs & Agents, Clinical Laboratory Sciences (RAE Unit 1), HIV Infection, Clinical Laboratory Science, Pharmacy, Community-based Clinical Subjects, Drug Delivery Systems, Pharmacy (RAE Unit 9)

Contact Details

Tel: +1 301 451 2732

Email: jturpin@niaid.nih.gov

IMAGING AND BIOMARKERS FOR EARLY CANCER DETECTION (R01) *NIH: National Cancer Institute*

Description:

The National Cancer Institute invites applications for its imaging and biomarkers for early cancer detection (R01) grants. This

R01 funding opportunity announcement aims to facilitate collaborative imaging and biomarker research to improve cancer screening, early cancer detection and

diagnosis by integrating multi-modality imaging strategies and multiplexed biomarker methodologies.

Application budgets are not limited, but must reflect actual needs of the project. Projects may last for up to five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-189

Closing date: 10 Jul 14

Deadline information: Deadlines on 10 July and 11 December annually until 12 December 2015

Posted date: 12 Apr 13

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award amount min: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-189.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-189>

Eligibility profile

Country of applicant institution: Any

Disciplines

Medical & Diagnostic Imaging, Cancer Biology, Breast Cancer, Cancer & Carcinogenesis, Prostate Cancer, Tumour Immunology, Chemotherapeutic Agents, Chemotherapy, Diagnosis, Medical, Biochemical Markers, Biological Markers, Oncology, Clinical Laboratory Sciences (RAE Unit 1), Hospital-based Clinical Subjects (RAE Unit 3), Anatomy (RAE Unit 6), Physiology (RAE Unit 7), Nursing (RAE Unit 10), Cancer Care, Leukaemia, Clinical Laboratory Science, Brain Tumour, Oncology Nursing, Multiple Myeloma, Blood Cancer, Cancer Nanotechnology, Hospital-based Clinical Subject, Lung Cancer, Ovarian Cancer, Colorectal Cancer/Colon Cancer/Bowel Cancer, Skin Cancer

Contact Details

Cancer Biomarkers Research Group
Division of Cancer Prevention
NCI
6130 Executive Boulevard, EPN Room 3100
Rockville, MD 20892
Tel: +1 301 496 8546
Email: richard.mazurchuk@nih.gov

DETECTION OF PATHOGEN-INDUCED CANCER (DPIC) (R01) *NIH: National Cancer Institute*

Description:

The National Cancer Institute invites applications for its detection of pathogen-induced cancer (R01) grants. This R01 funding opportunity announcement aims to encourage research project that focus on the interactions of carcinogenic pathogens with the human microbiome and the host for the detection of pathogen-induced cancer. This FOA

encourages research to assess molecular signatures associated with risk and early-detection of pathogen-induced cancer and chronic inflammation associated with progression to invasive cancer.

Application budgets are not limited, but must reflect actual needs of the project. Projects may last for up to five years. Domestic and

foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-190.

Closing date: 10 Jul 14

Deadline information: Deadlines on 10 July and 11 December annually until 12 December 2015. Applications due by 5pm local time of applicant organisation.

Posted date: 12 Apr 13

Award type: Directed grants to institutions, research groups etc

Award amount max: -

Award amount min: -

Award budget total: -

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-190.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-190>

Eligibility profile

Country of applicant institution: Any

Disciplines

Cancer Biology, Breast Cancer, Cancer & Carcinogenesis, Prostate Cancer, Tumour Immunology, Chemotherapeutic Agents, Chemotherapy, Diagnosis, Medical, Pathogenesis, Oncology, Clinical Laboratory Sciences (RAE Unit 1), Hospital-based Clinical Subjects (RAE Unit 3), Anatomy (RAE Unit 6), Physiology (RAE Unit 7), Nursing (RAE Unit 10), Cancer Care, Leukaemia, Clinical Laboratory Science, Brain Tumour, Oncology Nursing, Multiple Myeloma, Blood Cancer, Cancer Nanotechnology, Hospital-based Clinical Subject, Lung Cancer, Ovarian Cancer, Colorectal Cancer/Colon Cancer/Bowel Cancer, Skin Cancer

Contact Details

Division of Cancer Prevention
NCI
6130 Executive Boulevard, EPN 3146
Rockville, MD 20892
Tel: +1 301 435 1594
Email: kaganj@mail.nih.gov

N NIH AUDACIOUS GOAL INITIATIVE: ADDRESSING TECHNICAL NEEDS AND OPPORTUNITIES FOR IMAGING THE VISUAL SYSTEM (U01) *NIH: National Eye Institute*

Description:

The National Eye Institute invites applications for its audacious goal initiative in addressing technical needs and opportunities for imaging the visual system (U01) research grants. The purpose of this U01 funding opportunity is to encourage submission of new, innovative, transformative projects to address the technical needs and opportunities in the field of visual system imaging in order to focus and enable research efforts towards achieving the goals of the audacious goal initiative. The two areas of high programmatic priority are: understanding the intersection of ageing and

biological mechanisms of eye disease, and developing molecular therapies for eye disease.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. The estimated budget of US\$5 million to US\$6m will fund approximately four to six awards. Application budgets are limited to US\$700,000 annual direct costs. The maximum project period is five years.

Ref: RFA-EY-14-001.

Closing date: 14 Jul 14
Deadline information: Applications due by 5pm local time of applicant organisation.
Posted date: 30 Apr 14
Award type: Directed grants to institutions, research groups etc
Award amount max: \$700,000
Award budget total: \$6,000,000
Website:
<http://grants.nih.gov/grants/guide/rfa-files/RFA-EY-14-001.html>

Application form:
<http://www.grants.gov/applicants/apply-for-grants.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Molecular Genetics, Clinical Laboratory Sciences (RAE Unit 1), Optometry, Vision, Eye Diseases, Medical Genetics, Clinical Laboratory Science

Contact Details

Tel: +1 301 451 2020

Email: wiggsc@mail.nih.gov



I**NTEGRATED PRECLINICAL/CLINICAL AIDS VACCINE DEVELOPMENT PROGRAMME (U19)**

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases invites applications for its integrated preclinical/clinical Aids vaccine development programme (U19) grant. This U19 funding opportunity announcement aims to facilitate the translation of sufficiently advanced, innovative and promising vaccine candidates into early clinical testing.

The IPCAVD programme enables a multidisciplinary team of investigators to complete all steps necessary from down-selection of a vaccine candidate through Committee for Medicinal Products for Human Use manufacture, testing and product release and into clinical trials. Preclinical research applications alone are not sufficient for this announcement.

Awards provide the critical resources to allow the advancement of vaccine concepts to clinical trials within the first five years of the award. However, funds for conducting the clinical studies will not be provided and applicants are encouraged to collaborate with

NIAID-supported clinical networks or to develop other relationships to support the clinical studies. Investigators are expected to begin clinical studies no later than year five of the award.

NIAID anticipates that approximately US\$4 million total costs will be available in FY2014 to fund one to three awards. The approximate range of funding in direct cost has been between US\$1.5m and US\$2.5m per year. The total project period may not exceed five years.

Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions.

Ref: PAR-14-122 (replaces PA-13-042).

Closing date: 15 Jul 14

Deadline information: Applications due by 5pm local time of applicant organisation.

Deadlines on: 15 July 2014, 13 March 2015.

Posted date: 03 Mar 14

Award type: Directed grants to institutions, research groups etc

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-122.html>

Application form:

<https://public.era.nih.gov/assist/public/login.do>

Eligibility profile

Country of applicant institution: Any

Disciplines

Transmission of HIV/AIDS, Pharmacology, Pharmacy, AIDS, HIV Infection, Pharmaceuticals, Pharmacokinetics, Vaccine, Disease Prevention, Treatment, Medical, Drug Design, Viral Studies (Virology),

Pharmaceutical Chemistry, Toxicology, Clinical Laboratory Sciences (RAE Unit 1), Pre Clinical Studies (RAE Unit 5), Pharmacology (RAE Unit 8), Pharmacy (RAE Unit 9), Chemistry (RAE Unit 18), Clinical Pharmacology, Clinical Pharmacy, Clinical Laboratory Science, Pre-Clinical Studies, Immunisation Programmes, HIV Tests, Pharmacogenomics

Contact Details

NIHM
BG 6700B
Room 5136
6700B Rockledge Drive
Bethesda, MD 20817
Tel: +1 301 435 3749
Email: mpensiero@niaid.nih.gov

INNOVATION FOR HIV VACCINE DISCOVERY (R01)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Disease invites applications for its call on innovation for HIV vaccine discovery (R01). This R01 funding opportunity announcement will support high risk, high impact research to identify novel vaccine concepts and targets to aid in the design and long-term protection from acquisition of or ongoing infection by HIV. The call will emphasise early discovery research that incorporates new ideas leading to the development of newly engineered conventional or entirely novel approaches for vaccines with the potential for impact on the design of immunogens or strategies for an HIV vaccine. Applicants need not have previous research expertise in HIV prevention.

New and established investigators at US and foreign for-profit and non-profit organisations

and public or private institutions are eligible to apply.

NIAID will commit US\$2 million in fiscal year 2015 to fund four to five awards. Application budgets are limited to US\$350,000 per year in direct costs. A further US\$150,000 per year is available in any year when nonhuman primate research is proposed and justified. The maximum project period is four years.

Ref: RFA-AI-14-006.

Closing date: 15 Jul 14

Deadline information: Applications due by 5pm local time of applicant organisation.

Posted date: 19 Feb 14

Award type: Innovation grants, Directed grants to institutions, research groups etc

Award amount max: \$2,000,000

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-14-006.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=RFA-AI-14-006>

Eligibility profile

Country of applicant institution: Any

Disciplines

Immune System, Hospital-based Clinical Subject, Immunology, Hospital-based Clinical Subjects (RAE Unit 3), Transmission of

HIV/AIDS, Immunisation Programmes, Clinical Laboratory Sciences (RAE Unit 1), HIV Infection, Clinical Laboratory Science, Vaccine

Contact Details

NIAID
31 Center Drive
Bethesda, MD 20892
Tel: +1 301 402 0633
Email: jwarren@niaid.nih.gov

TARGETING LATENTLY INFECTED CELLS WITHOUT REACTIVATION (R01)

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases invites proposals for its call on targeting latently infected cells without reactivation (R01). This R01 funding opportunity announcement aims to advance understanding of mechanisms or approaches that could be harnessed to selectively eliminate HIV-1 latently infected cells without depending on viral reactivation. The goal is to inform the design of future therapeutic approaches that could be used to eradicate the latent reservoir that persists in the context of optimally suppressive highly active antiretroviral therapy, thereby affecting a permanent cure for HIV infection.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.

NIAID will provide US\$2.7 million in fiscal year 2015 to fund four to seven awards. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: RFA-AI-14-021.

Closing date: 15 Jul 14

Deadline information: Applications due by 5pm proposer's local time.

Posted date: 26 Mar 14

Award type: Directed grants to institutions, research groups etc

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-14-021.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=RFA-AI-14-021>

Eligibility profile

Country of applicant institution: Any

Disciplines

Nursing (RAE Unit 10), Therapeutics, Hospital-based Clinical Subjects (RAE Unit 3), Retrovirus, Community-based Clinical Subjects, Pharmacology (RAE Unit 8),

Hospital-based Clinical Subject, Viral Studies (Virology), HIV Infection, Community-based Clinical Subjects (RAE Unit 2)

Contact Details

NIAID
6700B Rockledge Drive,
Bethesda, MD 20892-7616
Tel: +1 301 435 3751
Email: embrya@mail.nih.gov

EPIDEMIOLOGY AND PREVENTION IN ALCOHOL RESEARCH (R21)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism invites applications for its epidemiology and prevention in alcohol research grants. The goal of this R21 funding opportunity is to encourage the submission of investigator-initiated research grant applications to support research investigating the epidemiology of alcohol use, alcohol-related harms, and alcohol use disorders and the prevention of underage drinking, alcohol-related harms, and alcohol use disorders. This mechanism will support investigation of novel scientific ideas or new model systems, tools or technologies that have the potential for significant impact on biomedical or biobehavioural research.

This funding opportunity announcement will utilise the NIH exploratory/developmental (R21) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-190, which solicits applications under the R01 research project grant mechanism, and PA-14-189, which solicits applications under the R03 small grant programme mechanism.

Direct costs are limited to US\$275,000 over a maximum period of two years, with no more than US\$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Ref: PA-14-188 (replaces PA-11-018).

Closing date: 16 Jul 14

Deadline information: Applications due by 5pm local time of applicant organisation on every 16 June, 16 November and 16 March until 8 September 2017. Deadlines on: 16 June 2014, 16 October 2014, 16 February 2015, and repeated annually.

Posted date: 28 Apr 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-188.html>

Application form:

<http://www.grants.gov/applicants/apply-for-grants.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Social & Economic Environment (Medical), Epidemiology, Psychology (RAE Unit 13), Addictions, Patient Care & Education, Alcohol & Alcoholism, Sociology (RAE Unit 42), Medical Sociology, Population Studies (Medical), Other Studies and Professions Allied to Medicine, Disease Prevention, Other Studies and Professions Allied to Medicine (RAE Unit 11), Behaviour & Health, Community-based Clinical Subjects (RAE Unit 2), Intervention, Types of (Health & Safety & Medical)

Contact Details

NIAAA
Building 5635FL, Room 2083
5635 Fishers Lane

Rockville MD 20852
Tel: +1 301 402 6328
Email: mscott@mail.nih.gov

S MALL GRANTS PROGRAM FOR CANCER EPIDEMIOLOGY (R03) *NIH: National Cancer Institute*

Description:

The National Cancer Institute invites applications for its small grants program for cancer epidemiology. The goal of this R03 funding opportunity announcement is to provide support for pilot projects, testing of new techniques, secondary analyses of existing data, development and validation of measurement methods, linkage of genetic polymorphisms with other variables related to cancer risk, and development of innovative projects for more comprehensive research in cancer etiology and epidemiology.

Applications will be accepted from domestic and foreign for-profit or non-profit organizations and public or private institutions. This funding opportunity will utilize the NIH R03 small grant award mechanism. Budgets for direct costs of up to \$50,000 per year for a project duration of up to two years may be requested. PAR-12-039 (replaces PAR-08-237)

Closing date: 22 Jul 14

Deadline information: Deadline: March 19, June 17, November 19, 2012; March 19, July 23, November 19, 2013; March 18, July 22, November 18, 2014.

Posted date: 29 Nov 11

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-12-039.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-039>

Eligibility profile

Country of applicant institution: Any

Disciplines

Breast Cancer, Cancer & Carcinogenesis, Prostate Cancer, Aetiology, Biochemical Markers, Biological Markers, Epidemiology, Oncology, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Clinical Laboratory Science, Blood Cancer, Community-based Clinical Subjects

Contact Details

Division of Cancer Control and Population Sciences
National Cancer Institute
6130 Executive Boulevard, EPN Room 5104, MSC 7324
Bethesda, MD 20892-7328
Tel: +1 301 594 7344
Fax: +1 301 402 4279
Email: vermam@mail.nih.gov

**LIMITED COMPETITION: PLANNING GRANT FOR FOGARTY HIV RESEARCH
TRAINING PROGRAMME FOR LOW- AND MIDDLE-INCOME COUNTRY
INSTITUTIONS (D71)**

NIH: Fogarty International Center

Description:

The Fogarty International Center and the National Institute of Mental Health invite applications for the limited competition: planning grant for Fogarty HIV research training programme for low- and middle-income country institutions (D71) grants. This D71 funding opportunity announcement supports research training that will strengthen the HIV research capacity of institutions in low- and middle-income countries. The planning grant application must propose a plan to develop the components necessary for an application for a research to D43 FOA. Applicants must be familiar with the objectives and special requirements of the research training programme.

Institutions in low and middle-income countries are eligible to apply. Application budgets are limited to US\$28,000 per year over two years. PAR-13-214 (replaces PAR-12-070).

Closing date: 24 Jul 14

Deadline information: Applications due by 5pm local time of applicant organisation. Deadlines on: 31 July 2013, 24 July 2014, 24 July 2015.

Posted date: 26 Apr 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$56,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-214.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-214>

Eligibility profile

Country of applicant institution: Lower-Middle-Income countries, Low Income countries, Upper-Middle-Income countries

Disciplines

Transmission of HIV/AIDS, AIDS, HIV Infection, Biomedical Research Training, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Clinical Laboratory Science, Community-based Clinical Subjects, Hospital-based Clinical Subject, HIV/AIDS, Social Aspects, HIV Tests

Contact Details

Fogarty International Center
31 Center Drive MSC 2220
Bethesda, MD 20892-2220
Tel: +1 301 496 1492
Email: jeanne.mcdermott@nih.gov

LIMITED COMPETITION: FOGARTY HIV RESEARCH TRAINING PROGRAMME FOR LOW- AND MIDDLE-INCOME COUNTRY INSTITUTIONS (D43)

NIH: Fogarty International Center

Description:

The Fogarty International Center, the National Cancer Institute, the National Institute on Drug Abuse and the National Institute of Mental Health invite applications for their limited competition: Fogarty HIV research training programme for low- and middle-income country institutions (D43) programme. This D43 funding opportunity announcement aims to support research training programmes to develop and strengthen the scientific leadership and expertise needed for HIV-related research at eligible low- and middle-income country institutions. This FOA can support training for a broad range of HIV research areas:

- all basic, epidemiologic, clinical, behavioural, social science, implementation, operations, health services and health systems research across HIV prevention, care and treatment;
- research on HIV co-infections, Aids-defining and HIV-related cancers, comorbidities and other health conditions, both infectious and non-infectious, that contribute to HIV transmission or poor health in HIV-infected individuals;
- research and research methodology for community-based research, complex and multi-component interventions, for structural interventions, for comparative effectiveness research, for impact evaluation or for health economics;
- HIV-related research among vulnerable or under-researched LMIC populations, including women, children, substance users, men who have sex with men, transgendered populations, ageing populations, orphans and vulnerable children;

- training for clinical research team members to support clinical research and clinical trials;
- bio-statistics for research design and methodology, data analysis, data management, and data quality assurance and control;
- laboratory capacity, bio-safety and maintenance of lab quality assurance and control.

Institutions in low- and middle-income countries are eligible to apply.

Application budgets are limited to US\$282,000 per year over five years. PAR-13-126 (replaces PAR-12-068).

Closing date: 24 Jul 14

Deadline information: Applications due by 5pm local time of applicant organisation. Deadlines on: 31 July 2013, 24 July 2014, 24 July 2015.

Posted date: 26 Apr 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$1,410,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-126.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-216>

Eligibility profile

Country of applicant institution: Lower-Middle-Income countries, Low Income countries, Upper-Middle-Income countries

Disciplines

Transmission of HIV/AIDS, Behaviour & Health, AIDS, HIV Infection, Biomedical

Research Training, Vital Statistics, Preventive Medicine, Epidemiology, Data Analysis, Data Acquisition, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Psychology (RAE Unit 13), Statistics and Operational Research (RAE Unit 24), Computer Science (RAE Unit 25), Clinical Laboratory Science, Community-based Clinical Subjects, Hospital-based

Clinical Subject, HIV/AIDS, Social Aspects, HIV Tests, Transgender/Intergender studies

Contact Details

Fogarty International Center
31 Center Drive MSC 2220
Bethesda, MD 20892-2220
Tel: +1 301 496 1492
Email: jeanne.mcdermott@nih.gov



CHRONIC WOUNDS: ADVANCING THE SCIENCE FROM PREVENTION TO HEALING (R01) *NIH: National Institute of Nursing Research*

Description:

The National Institute of Nursing Research invites applications for its chronic wounds: advancing the science from prevention to healing (R01) grant. The purpose of this funding announcement is to stimulate research that will increase the understanding of biological and psychosocial factors associated with development, progression, and repair of chronic wounds and associated adverse outcomes, and to develop and test interventions aimed at preventing the onset of chronic wounds, expediting the healing process, or alleviating wound-related symptoms. NINR is primarily interested in applications focusing on clinical research (including studies that develop and/or test clinical interventions), but recognises that certain studies may be restricted to animal models at present because appropriate human research models are not available, or human studies are otherwise not feasible. Applications that include animal studies should provide a rationale for why the use of the animal model is essential for the research proposed. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

NINR intends to commit US\$3 million in FY2015 to support up to six awards. Application budgets are limited to US\$350,000 in direct costs in any year. The maximum project period is five years.

Ref: RFA-NR-15-001.

Closing date: 24 Jul 14

Deadline information: Optional letters of intent due by 24 June; applications due by 5pm local time of applicant organisation, 24 July 2014.

Posted date: 07 May 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$350,000

Award budget total: \$3,000,000

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-NR-15-001.html>

Application form:

<http://www.grants.gov/applicants/apply-for-grants.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Clinical Medicine, General, Wound Healing, Clinical Dentistry (RAE Unit 4), Health Promotion, Community-based Clinical Subjects (RAE Unit 2), Anatomy (RAE Unit 6), Hospital-based Clinical Subjects (RAE Unit 3), Cardiology, Injury Prevention, Chronic Diseases, Other Studies and Professions Allied to Medicine (RAE Unit 11), Ulcers, Disease Prevention, Infectious Diseases &

Agents, Neurological Disorders, Injury, Immunophysiology, Preventive Medicine

Contact Details

NIH NINR
31 Center Drive, Room 5B10
Bethesda MD 20892-2178
Tel: +1 301 594 5968
Fax: +1 301 496 8845
Email: tullyla@mail.nih.gov

R ESearch in Latent Tuberculosis Infection in the Setting of HIV Co-Infection (R01) *NIH: National Institute of Allergy and Infectious Diseases*

Description:

The National Institute of Allergy and Infectious Diseases invites applications for its research in latent tuberculosis infection in the setting of HIV co-infection (R01) programme. This R01 funding opportunity announcement invites grant applications which propose research to increase the understanding of the microbiologic adaptive mechanisms, host immunologic factors, and their interactions involved in the development, maintenance, and activation of LTBI with a focus on HIV co-infection.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-061

Closing date: 25 Jul 14

Deadline information: Deadlines on: 25 July 2013, 25 July 2014, 24 July 2015.

Posted date: 27 Dec 12

Award type: Directed grants to institutions, research groups etc

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-061.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-061>

Eligibility profile

Country of applicant institution: Any

Disciplines

Medical & Diagnostic Imaging, Immunology, HIV Infection, Tuberculosis, Immunotherapy, Bioassay, Biochemical Markers, Biological Markers, Drug Resistance, Microbial Processes, Microbiology, Clinical Laboratory Sciences (RAE Unit 1), Biological Sciences (RAE Unit 14), Clinical Laboratory Science

Contact Details

Division of Aids
NIAID
6610 Rockledge Drive, MSC 6612
Bethesda, MD 20892-6612
Tel: +1 301 402 5765
Email: sudha.srinivasan@nih.gov

G **RAND OPPORTUNITY IN MEDICATIONS DEVELOPMENT FOR SUBSTANCE-USE DISORDERS (U01)** NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its grand opportunity in medications development for substance-use disorders (U01). This U01 funding opportunity announcement will support a diverse array of preclinical and clinical projects to accelerate the development of medication for the treatment of substance-use disorders. The goal is to fund medication studies that will have a high impact and quickly yield the necessary results to advance medications closer to approval by the US Food and Drug Administration. The aim is to enable critical medications development studies that would not be possible using traditional means.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

The NIH intends to commit US\$10 million to fund two to three awards in fiscal year 2013. Application budgets are limited to US\$5m a year over a three-year period. PAR-13-270

Closing date: 28 Jul 14

Deadline information: Applications due by 5pm local time of applicant organisation. Deadlines on: 27 March 2014, 28 July 2014, 27 March 2015, 28 July 2015, 28 March 2016, 28 July 2016.

Posted date: 12 Jul 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$15,000,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-270.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-270>

Eligibility profile

Country of applicant institution: Any

Disciplines

Drug & Substance Abuse, Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Pharmacology (RAE Unit 8), Pharmacy (RAE Unit 9), Community-based Clinical Subjects, Hospital-based Clinical Subject, Pharmacy, Clinical Trial, Clinical Medicine, General, Clinical Laboratory Sciences (RAE Unit 1), Pre Clinical Studies (RAE Unit 5), Clinical Pharmacology, Clinical Laboratory Science, Pre-Clinical Studies, Medication Studies

Contact Details

Division of Pharmacotherapies and Medical Consequences of Drug Abuse
NIDA
NIH
9000 Rockville Pike
Bethesda, MD 20892
Tel: +1 301 443 8639
Email: imontoya@mail.nih.gov

S TRATEGIC ALLIANCES FOR MEDICATIONS DEVELOPMENT TO TREAT SUBSTANCE USE DISORDERS (R01) NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its strategic alliances for medications development to treat substance use disorders (R01). The purpose of this R01 funding opportunity announcement is to support research that advances compounds towards US Food and Drug Administration approval by leveraging NIDA funds with the strengths and resources of outside organisations, such as for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations and small businesses. Applications from single entities that possess considerable resources for medications development will also be considered, provided the entity demonstrates a significant resource commitment to the proposed project.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

Application budgets for direct costs may be up to \$2 million per year, but need to reflect the actual needs of the proposed project. The maximum period of support is three years. PAR-13-334 (Reissue of PAS-12-122).

Closing date: 28 Jul 14

Deadline information: Applications due by 5pm local time of applicant organisation. Deadlines on: 27 March 2014, 28 July 2014, 27 March 2015, 28 July 2015, 28 March 2016, 28 July 2016.

Posted date: 20 Aug 13

Award type: Directed grants to institutions, research groups etc, Academic-Industry links, Clinical trials, Networking/collaboration

Award amount max: \$6,000,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-334.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-334>

Eligibility profile

Country of applicant institution: Any

Disciplines

Drug & Substance Abuse, Pharmacology, Pharmacy, Drug Delivery Systems, Pharmaceuticals, Drug Design, Clinical Laboratory Sciences (RAE Unit 1), Pharmacology (RAE Unit 8), Pharmacy (RAE Unit 9), Clinical Laboratory Science, Medication Studies

Contact Details

Division of Pharmacotherapies and Medical Consequences of Drug Abuse
NIDA
6001 Executive Boulevard
Bethesda, MD 20892-9561
Tel: +1 301 443 8096
Email: jb168r@nih.gov

A VANT-GARDE AWARD PROGRAMME FOR HIV/AIDS AND DRUG USE RESEARCH (DP1) NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites for its avant-garde award programme for HIV/Aids and drug use research. This DP1 funding opportunity supports individual scientists of exceptional creativity who propose innovative, high-impact basic research that will open new areas of HIV/Aids research or lead to new avenues for prevention and treatment of HIV/Aids among drug abusers. Research may lead to improved prevention interventions or therapies; creative, new strategies to prevent disease transmission; novel approaches to improve disease outcomes; and creative approaches to eradicating HIV or improving the lives of those living with HIV.

US or foreign for-profit and non-profit organisations may apply.

NIDA intends to commit US\$2 million in FY2015, to fund two to three awards each year. Applicants may request direct costs of up to US\$500,000 per year, over a maximum of five years.

Ref: RFA-DA-15-004 (reissue of RFA-DA-14-008).

Closing date: 29 Jul 14

Deadline information: Proposals due by 5pm applicant's local time.

Posted date: 14 Feb 14

Award type: Innovation grants, Directed grants to institutions, research groups etc

Award amount max: \$2,500,000

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-15-004.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=RFA-DA-15-004>

Eligibility profile

Country of applicant institution: Any

Disciplines

Treatment, Medical, Patient Outcomes, Drug & Substance Abuse, Community-based Clinical Subjects, Transmission of HIV/AIDS, Disease Prevention, HIV Infection, Clinical Laboratory Science, AIDS, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2)

Contact Details

NIDA

6001 Executive Boulevard

Rockville, MD 20852

Tel: +1 301 443 1470

Email: jnormand@nida.nih.gov

A DVANCING EXCEPTIONAL RESEARCH ON HIV/AIDS AND SUBSTANCE ABUSE (R01) NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its advancing exceptional research on HIV/Aids and substance abuse

(R01) programme. This R01 funding opportunity announcement will support highly innovative applications on HIV/Aids and drug abuse. The focus is on innovative

research projects that have the potential to open new areas of HIV/Aids research or lead to new avenues for prevention and treatment of HIV/Aids among substance abusers. The applicant should clearly describe the nexus of substance abuse. This call is not limited to any one area of research. This FOA will complement the NIH avant-garde programme.

This FOA is open to both individual researchers and research teams. Applications may be submitted by foreign or US for-profit and non-profit organisations and public or private institutions.

NIDA intends to commit US\$2 million in fiscal year 2015 to fund two to three awards. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: RFA-DA-15-005 (replaces RFA-DA-14-003).

Closing date: 31 Jul 14

Deadline information: Applications due by 5pm proposer's local time.

Posted date: 06 Feb 14

Award type: Directed grants to institutions, research groups etc, Directed grants for individual investigators

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-15-005.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application->

Eligibility profile

Country of applicant institution: Any

Disciplines

Disease Prevention, Transmission of HIV/AIDS, Hospital-based Clinical Subjects (RAE Unit 3), Intervention, Agents for (Health & Safety & Medical), Hospital-based Clinical Subject, AIDS Counselling, Treatment, Medical, Community-based Clinical Subjects, Drug & Substance Abuse, Clinical Laboratory Science, HIV Infection, Clinical Laboratory Sciences (RAE Unit 1), Preventive Medicine, AIDS, HIV Tests, Intervention, Types of (Health & Safety & Medical), Community-based Clinical Subjects (RAE Unit) package.html#download=true?opp Number RFA-DA-15-005

Contact Details

NIDA
6001 Executive Boulevard
Bethesda, MD 20892
Tel: +1 301 443 1470
Email: jnormand@nida.nih.gov



AUGUST 2014

NEURONEXT CLINICAL TRIALS (U01)

NIH: National Institute of Neurological Disorders and Stroke

Description:

The National Institute of Neurological Disorders and Stroke invites applications for its NeuroNEXT clinical trials (U01) grants. This U01 funding opportunity announcement encourages exploratory clinical trials investigational agents that may contribute to the justification for and provide the data required to design a future trial for biomarker validation studies or for proof-of-mechanism clinical studies. Diseases studied must correlate with NINDS's strategic plan and clinical research interests.

Application budgets are not limited, but need to reflect actual needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Non-US entities may apply, but they will have to work with the US-based NeuroNEXT infrastructure. PAR-13-343 (replaces PAR-11-343).

Closing date: 01 Aug 14

Deadline information: Applications due by 5pm local time of applicant organisation

Deadlines on: 2 December 2013, 2 April 2014, 1 August 2014, 2 December 2014, 3 April 2015, 3 August 2015, 3 December 2015.

Posted date: 02 Sep 13

Award type: Directed grants to institutions, research groups etc

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-343.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-343>

Eligibility profile

Country of applicant institution: Any

Disciplines

Disease Prevention, Clinical Trial, Biochemical Markers, Biological Markers, Research Resources (Health & Safety & Medical), Clinical Laboratory Sciences (RAE Unit 1), Hospital-based Clinical Subjects (RAE Unit 3), Clinical Laboratory Science, Hospital-based Clinical Subject

Contact Details

NINDS
6001 Executive Boulevard
Bethesda, MD 20892
Tel: +1 301 496 9135
Email: mcneilde@ninds.nih.gov

HIGH THROUGHPUT SCREENING TO DISCOVER CHEMICAL PROBES (R03)

NIH: National Institute of Mental Health

Description:

Five institutes and centres of the National Institutes of Health invite applications for

their high throughput screening to discover chemical probes (R03) grants. This R03 funding opportunity announcement aims to

promote and support discovery and development of new chemical probes as research tools for use to advance understanding of biological functions and disease mechanisms. The FOA encourages partnerships between assay submitters and a discovery facility to conduct joint research. Funding will stimulate research in:

- the discovery and development of novel, small molecules for their potential use in studying disease treatment;
- the discovery or validation of novel, biological targets that will inform studies of disease mechanisms.

Direct costs are limited to US\$100,000 over a two-year period, with no more than US\$50,000 in direct costs allowed in any single year. Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. PAR-13-135.

Closing date: 06 Aug 14

Deadline information: Applications due by 5pm local time of applicant organisation. Deadlines on: 6 August 2013, 4 December 2013, 4 April 2014, 6 August 2014, 4 December 2014, 3 April 2015, 6 August 2015, 4 December 2015.

Posted date: 07 Mar 13

Award type: Directed grants to institutions, research groups etc, Networking/collaboration, Innovation grants

Award amount max: \$100,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-135.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-135>

Eligibility profile

Country of applicant institution: Any

Disciplines

Biomedical, Medical Sciences, Health, Medicinal Chemistry, Disease Entities & Medical Problems & Behaviour, Bioassay, Disease Model, Molecular Probes, Clinical Laboratory Sciences (RAE Unit 1), Chemistry (RAE Unit 18), Clinical Laboratory Science

Contact Details

Division of Neuroscience and Basic Behavioral Science
NIMH
6001 Executive Boulevard, Room 7182B, MSC 9641
Bethesda, MD 20892-9641
Tel: +1 301 443 6102
Email: yyao@mail.nih.gov

MULTIDISCIPLINARY STUDIES OF HIV/AIDS AND AGEING (R21) *NIH: National Institute on Aging*

Description:

A total of nine institutes of the National Institutes of Health invite applications for their multidisciplinary studies of HIV/Aids and ageing (R21) programme. This R21 funding opportunity announcement will support studies of HIV infection, HIV-associated conditions, HIV treatment or

biobehavioural or social factors associated with HIV/Aids research in the context of ageing or in older adults. Research approaches of interest include clinical translational, observational and intervention studies in domestic and international settings.

This FOA will use the R21 exploratory/developmental research grant award and runs in parallel with two FOAs of identical scope, PAR-12-175, which uses the R01 research project grant mechanism and PAR-12-176, which uses the R03 small grant mechanism.

Application budgets are limited to US\$275,000 over a two-year project period, with no more than US\$200,000 in direct costs allowed in any year. Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions. PAR-12-174.

Closing date: 07 Aug 14

Deadline information: Deadlines on: 7 August 2012, 7 December 2012, 9 April 2013, 7 August 2013, 10 December 2013, 9 April 2014, 7 August 2014, 9 December 2014, 7 April 2015.

Posted date: 25 Apr 12

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-12-174.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFormFedgrants?opportunity=PAR-12-174>

Eligibility profile

Country of applicant institution: Any

Disciplines

Transmission of HIV/AIDS, Ageing & Gerontology, Disease Entities & Medical Problems & Behaviour, AIDS, Breast Cancer, Cancer & Carcinogenesis, HIV Infection, Prostate Cancer, Intervention, Types of (Health & Safety & Medical), Treatment, Medical, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Anatomy (RAE Unit 6), Physiology (RAE Unit 7), Leukaemia, Clinical Laboratory Science, Blood Cancer, Community-based Clinical Subjects, Hospital-based Clinical Subject, Physiology, Lung Cancer, Ovarian Cancer, Colorectal Cancer/Colon Cancer/Bowel Cancer, Skin Cancer

Contact Details

NIA

7201 Wisconsin Avenue

Bethesda, MD 20892

Tel: +1 301 496 6761

Email: basil.eldadah@nih.gov

MULTIDISCIPLINARY STUDIES OF HIV/AIDS AND AGEING (R01) *NIH: National Institute on Aging*

Description:

A total of eleven institutes of the National Institutes of Health invite applications for their multidisciplinary studies of HIV/Aids and ageing (R01) programme. This R01 funding opportunity announcement will support studies of HIV infection, HIV-associated conditions, HIV treatment or

biobehavioural or social factors associated with HIV/Aids research in the context of ageing or in older adults. Research approaches of interest include clinical translational, observational and intervention studies in domestic and international settings.

This FOA will use the R01 research project grant and runs in parallel with two FOAs of identical scope, PAR-12-174, which uses the R21 exploratory/developmental research grant mechanism and PAR-12-176, which uses the R03 small grant mechanism.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions. PAR-12-175.

Closing date: 07 Aug 14

Deadline information: Deadlines on: 7 August 2012, 7 December 2012, 9 April 2013, 7 August 2013, 10 December 2013, 9 April 2014, 7 August 2014, 9 December 2014, 7 April 2015.

Posted date: 25 Apr 12

Award type: Directed grants to institutions, research groups etc

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-12-175.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFormFedgrants?opportunity=PAR-12-175>

Eligibility profile

Country of applicant institution: Any

Disciplines

Transmission of HIV/AIDS, Ageing & Gerontology, Disease Entities & Medical Problems & Behaviour, AIDS, Breast Cancer, Cancer & Carcinogenesis, HIV Infection, Prostate Cancer, Intervention, Types of (Health & Safety & Medical), Treatment, Medical, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Anatomy (RAE Unit 6), Physiology (RAE Unit 7), Leukaemia, Clinical Laboratory Science, Blood Cancer, Community-based Clinical Subjects, Hospital-based Clinical Subject, Physiology, Lung Cancer, Ovarian Cancer, Colorectal Cancer/Colon Cancer/Bowel Cancer, Skin Cancer

Contact Details

NIA

7201 Wisconsin Avenue

Bethesda, MD 20892

Tel: +1 301 496 6761

Email: basil.eldadah@nih.gov

MULTIDISCIPLINARY STUDIES OF HIV/AIDS AND AGEING (R03) *NIH: National Institute on Aging*

Description:

A total of six institutes of the National Institutes of Health invite applications for their multidisciplinary studies of HIV/Aids and ageing (R03) programme. This R03 funding opportunity announcement will support studies of HIV infection, HIV-associated conditions, HIV treatment or biobehavioural or social factors associated with HIV/Aids research in the context of ageing or in older adults. Research

approaches of interest include clinical translational, observational and intervention studies in domestic and international settings.

This FOA will use the R03 small grant mechanism and runs in parallel with two FOAs of identical scope, PAR-12-174, which uses the R21 exploratory/developmental research grant mechanism and PAR-12-175, which uses the R03 research project grant.

Application budgets are limited to US\$100,000 over a two-year project period, with no more than US\$50,000 in direct costs allowed in any year. Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions. PAR-12-176.

Closing date: 07 Aug 14

Deadline information: Deadlines on: 7 August 2012, 7 December 2012, 9 April 2013, 7 August 2013, 10 December 2013, 9 April 2014, 7 August 2014, 9 December 2014, 7 April 2015.

Posted date: 25 Apr 12

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Website:<http://grants.nih.gov/grants/guide/pa-files/PA-12-176.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFormFedgrants?opportunity=PAR-12-176>

Eligibility profile

Country of applicant institution: Any

Disciplines

Transmission of HIV/AIDS, Ageing & Gerontology, Disease Entities & Medical Problems & Behaviour, AIDS, Breast Cancer, Cancer & Carcinogenesis, HIV Infection, Prostate Cancer, Intervention, Types of (Health & Safety & Medical), Treatment, Medical, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Anatomy (RAE Unit 6), Physiology (RAE Unit 7), Leukaemia, Clinical Laboratory Science, Blood Cancer, Community-based Clinical Subjects, Hospital-based Clinical Subject, Physiology, Lung Cancer, Ovarian Cancer, Colorectal Cancer/Colon Cancer/Bowel Cancer, Skin Cancer

Contact Details

NIA
7201 Wisconsin Avenue
Bethesda, MD 20892
Tel: +1 301 496 6761
Email: basil.eldadah@nih.gov

TRANSLATIONAL RESEARCH IN PAEDIATRIC AND OBSTETRIC PHARMACOLOGY (R03)

NIH: National Institute of Child Health and Human Development

Description:

The National Institute of Child Health and Human Development invites applications for translational research in paediatric and obstetric pharmacology (R03) grants. This R03 funding opportunity announcement funds translational and clinical research and clinical trials to advance knowledge about the underlying mechanisms of drug action, response and safety in children and developing foetuses. The overall goals of this funding opportunity announcement are:

- to improve the safety and effectiveness of current drugs for paediatric or obstetric patients;
- to enhance the development of new drugs or a safer usage of the existing drugs for tailored therapies to meet emerging clinical needs for these special populations.

This FOA will use the R03 award mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-309 that encourages applications under the R01 grant mechanism

and PAR-13-311 that encourages applications under the R21 grant mechanism. Budgets for direct costs of up to US\$50,000 per year and a project duration of up to two years may be requested. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PAR-13-310 (replaces PAR-11-247).

Closing date: 14 Aug 14

Deadline information: Applications due by 5pm proposer's local time.

Posted date: 06 Aug 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-310.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFormFedgrants?opportunity=PAR-13-310>

Eligibility profile

Country of applicant institution: Any

Disciplines

Foetus, Pharmacology, Neonatal Disorders, Perinatal Disorders, Pregnancy Disorders, Child & Maternal Health, Biological Markers, Perinatal Health, Pregnancy, Medical Genetics, Obstetrics & Gynaecology, Paediatrics, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Pharmacology (RAE Unit 8), Biological Sciences (RAE Unit 14), Genomics, Clinical Laboratory Science, Community-based Clinical Subjects, Hospital-based Clinical Subject, Translational Medicine, Epigenomics

Contact Details

Obstetric and Paediatric Pharmacology and Therapeutics Branch
NICHD
6100 Executive Boulevard
Room 4A01D MSC 7510
Bethesda, MD 20892-7510
Tel: +1 301 402 9340
Email: zren@mail.nih.gov

T RANSLATIONAL RESEARCH IN PAEDIATRIC AND OBSTETRIC PHARMACOLOGY (R01) *NIH: National Institute of Child Health and Human Development*

Description:

The National Institute of Child Health and Human Development invites applications for its translational research in paediatric and obstetric pharmacology (R01) grants. This R01 funding opportunity announcement funds translational and clinical research and clinical trials to advance knowledge about the underlying mechanisms of drug action, response and safety in children and developing foetuses. The overall goals of this funding opportunity announcement are:

- to improve the safety and effectiveness of current drugs for paediatric or obstetric patients;
- to enhance the development of new drugs or a safer usage of the existing drugs for tailored therapies to meet emerging clinical needs for these special populations.

This FOA will use the R01 award mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-310 that encourages applications under the R03 grant mechanism and PAR-13-311 that encourages applications

under the R21 grant mechanism. Application budgets are not limited but need to reflect the actual needs of the project. The maximum project period is five years. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PAR-13-309 (replaces PAR-11-246).

Closing date: 14 Aug 14

Deadline information: Applications due by 5pm proposer's local time.

Posted date: 06 Aug 13

Award type: Directed grants to institutions, research groups etc

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-309.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFormFedgrants?opportunity=PAR-13-309>

Eligibility profile

Country of applicant institution: Any

Disciplines

Foetus, Pharmacology, Neonatal Disorders, Perinatal Disorders, Pregnancy Disorders, Child & Maternal Health, Biological Markers, Perinatal Health, Pregnancy, Medical Genetics, Obstetrics & Gynaecology, Paediatrics, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Pharmacology (RAE Unit 8), Biological Sciences (RAE Unit 14), Genomics, Clinical Laboratory Science, Community-based Clinical Subjects, Hospital-based Clinical Subject, Translational Medicine, Epigenomics

Contact Details

Obstetric and Paediatric Pharmacology and Therapeutics Branch
NICHD
6100 Executive Boulevard
Room 4A01D MSC 7510
Bethesda, MD 20892-7510
Tel: +1 301 402 9340
Email: zren@mail.nih.gov

T RANSLATIONAL RESEARCH IN PAEDIATRIC AND OBSTETRIC PHARMACOLOGY (R21) *NIH: National Institute of Child Health and Human Development*

Description:

The National Institute of Child Health and Human Development invites applications for translational research in paediatric and obstetric pharmacology (R21) grants. This R21 funding opportunity announcement funds translational and clinical research and clinical trials to advance knowledge about the underlying mechanisms of drug action, response and safety in children and developing fetuses. The overall goals of this funding opportunity announcement are:

- to improve the safety and effectiveness of current drugs for paediatric or obstetric patients;
- to enhance the development of new drugs or a safer usage of the existing drugs for tailored therapies to meet emerging clinical needs for these special populations.

This FOA will use the R21 award mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-310 that encourages applications under the R03 grant mechanism and PAR-13-309 that encourages applications

under the R01 grant mechanism. Direct costs are limited to US\$275,000 over an R21 two-year period. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PAR-13-311 (replaces PAR-11-248).

Closing date: 14 Aug 14

Deadline information: Applications due by 5pm proposer's local time.

Posted date: 06 Aug 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-311.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-311>

Eligibility profile

Country of applicant institution: Any

Disciplines

Foetus, Pharmacology, Neonatal Disorders, Perinatal Disorders, Pregnancy Disorders, Child & Maternal Health, Biological Markers, Perinatal Health, Pregnancy, Medical Genetics, Obstetrics & Gynaecology, Paediatrics, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Pharmacology (RAE Unit 8), Biological Sciences (RAE Unit 14), Genomics, Clinical Laboratory Science, Community-based Clinical Subjects, Hospital-based Clinical Subject, Translational Medicine, Epigenomics

Contact Details

Obstetric and Paediatric Pharmacology and Therapeutics Branch
NICHD
6100 Executive Boulevard
Room 4A01D MSC 7510
Bethesda, MD 20892-7510
Tel: +1 301 402 9340
Email: zren@mail.nih.gov

CUTTING-EDGE BASIC RESEARCH AWARDS (R21)

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its cutting-edge basic research awards (R21). These R21 grants support highly innovative or conceptually creative research that advances understanding of drug abuse and addiction and how to prevent and treat them. This scheme is specifically designed to support research that is high risk and potentially high impact and that is underrepresented or not included in NIDA's current portfolio. The proposed research should:

- test a highly novel and significant hypothesis for which there is significantly scant precedent or preliminary data and which, if confirmed, would have a substantial impact on current thinking;
- develop or adapt innovative techniques or methods for addiction research or have promising future applicability for drug abuse research.

This funding opportunity will use the R21 award mechanism. Budgets are limited to US\$125,000 per year in direct costs over a two-

year project period. Domestic and foreign for-profit and nonprofit organizations and public or private institutions may apply. PAR-12-086 (replaces PAR-09-222)

Closing date: 20 Aug 14

Deadline information: Applications are due 5pm local time of applicant organization on deadline date. Deadlines on: 20 August 2012, 20 December 2012, 20 August 2013, 20 December 2013, 20 August 2014, 19 December 2014.

Posted date: 30 Jan 12

Award type: Directed grants to institutions, research groups etc

Award amount max: \$250,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-12-086.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFormFedgrants?opportunity=PAR-12-086>

Eligibility profile

Country of applicant institution: Any

Disciplines

Addictions, Drug & Substance Abuse, Neurophysiology, Neuropharmacology, Neuroscience, Community-based Clinical Subjects (RAE Unit 2), Physiology (RAE Unit 7), Pharmacology (RAE Unit 8), Psychology (RAE Unit 13), Biological Sciences (RAE Unit 14), Neurobiology, Community-based Clinical Subjects, Physiology, Psychology, Pharmacology

Contact Details

Division of Basic Neuroscience and Behavioral Research

NIDA

6001 Executive Boulevard, Room 4282, MSC 9555

Bethesda, MD 20892-9555

Tel: +1 301 435 1315

Fax: +1 301 594 6043

Email: svolman@mail.nih.gov

INTERNATIONAL RESEARCH IN INFECTIOUS DISEASES (R01): AIDS-RELATED

NIH: National Institute of Allergy and Infectious Diseases

Description:

The National Institute of Allergy and Infectious Diseases invites applications for funding for international research in infectious diseases. This Aids-related R01 funding opportunity announcement solicits applications from organisations and institutions in resource-constrained countries that propose research related to infectious diseases. The intent is to advance the development of local scientific expertise, build local research infrastructure and to increase collaborative research partnerships at NIAID international sites.

For-profit or non-profit organisations and public or private institutions in developing countries may apply. Principal investigators may not currently hold a NIH funded grant. Collaborative projects involving investigators and institutions from international sites and the US are particularly encouraged, but a US partner is not a requirement.

Grants are worth up to US\$125,000 per year over a period of up to five years.

PAR-14-080 (replaces PAR-11-145).

Closing date: 22 Aug 14

Deadline information: Application due by 5pm local time of applicant organisation. Deadlines on: 22 August 2014, 19 August 2015, 21 August 2015.

Posted date: 31 Jan 14

Award type: Networking/collaboration, Directed grants to institutions, research groups etc

Award amount max: \$625,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-080.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-11-145>

Eligibility profile

Country of applicant institution: Lower-Middle-Income countries, Low Income countries, Upper-Middle-Income countries

Disciplines

HIV Infection, Physiology (RAE Unit 7), Vector-Borne Disease, Clinical Laboratory Science, Tuberculosis, Epidemiology, Biological Sciences (RAE Unit 14), Enteric Diseases, Influenza, Tropical Medicine,

HIV/AIDS, Social Aspects, HIV Tests, Community-based Clinical Subjects (RAE Unit 2), AIDS, Respiratory System, Pathogenesis, Clinical Laboratory Sciences (RAE Unit 1), Immunopathology, Immunology, Sexually Transmitted Diseases, Drug Resistance, Anatomy (RAE Unit 6), Transmission of HIV/AIDS, Other Studies and Professions Allied to Medicine (RAE Unit 11), Malaria, Other Studies and Professions Allied to Medicine, Immune System, International Health, Parasitic Diseases, Infectious Diseases & Agents, Community-based Clinical Subjects, Biostatistics, Viral Studies (Virology), Microbiology, Lung Disease

Contact Details

Division of Microbiology and Infectious Diseases

NIAID

Room 3807, MSC-6603

6610 Rockledge Drive

Bethesda, MD 20892-6603

Tel: +1 301 496 1884

Email: ps31g@nih.gov

TARGETING CO-DEPENDENT MOLECULAR PATHWAYS IN ORAL CANCER (U01) *NIH: National Institute of Dental and Craniofacial Research*

Description:

The National Institute of Dental and Craniofacial Research invites application for its targeting co-dependent molecular pathways in oral cancer (U01) grants. The purpose of this U01 funding opportunity is to support multi-disciplinary projects aimed at the development of new targeted and effective therapies through systematic use and leveraging of recently identified genomic abnormalities and attendant changes in gene or protein expression profiles in human oral

cancer samples. The goal of this FOA is the identification of co-dependent survival and proliferation pathways in oral cancer cells and the elucidation of potential signaling pathways that can be targeted with combination therapy approaches. This initiative requires collaboration of multi-disciplinary research teams that include cancer biologists, computational biologists, model system specialists and/or screening assay specialists. The emphasis will be on the

conceptual phase of target identification and exploration including proof-of-concept phase.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

This U01 is limited to direct cost requests of up to US\$6000, 000 over the entire project period. The maximum project period is four years. It is anticipated that three to four projects will receive funding. Ref: RFA-DE-15-004

Closing date: 25 Aug 14

Deadline information: Applications due by 5pm local time of applicant organisation.

Posted date: 23 Apr 14

Award type: Networking/collaboration, Directed grants to institutions, research groups etc

Award amount max: \$600,000

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DE-15-004.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Hospital-based Clinical Subject, Oral Diseases, Oncology, Hospital-based Clinical Subjects (RAE Unit 3), Oral Medicine, Nursing (RAE Unit 10), Cancer Care, Clinical Laboratory Sciences (RAE Unit 1), Screening For Diseases, Clinical Dentistry (RAE Unit 4), Medical and Biotechnology (Diagnostics), Clinical Laboratory Science

Contact Details

Tel: +1 301 594 4812

Email: sundarv@nih.gov



SEPTEMBER, 2014

S MALL GRANTS PROGRAMME FOR CANCER RESEARCH (R03): AIDS-RELATED *NIH: National Cancer Institute*

Description:

The National Cancer Institute invites applications for its Aids-related small grants programme for cancer research (R03). This Aids-related R03 funding opportunity announcement supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology and development of new research technology.

This funding opportunity will use the small grant programme (R03) mechanism, and runs in parallel with an FOA of identical scientific scope, PAR-13-146, which solicits applications under the exploratory/developmental (R21) award mechanism.

Applicants may request direct costs of up to US\$50,000 per year over a two-year project period. Domestic and foreign for-profit or non-profit organisations and public or private institutions are eligible to apply.

Ref: PAR-14-007 (replaces PAR-12-144).

Closing date: 05 Sep 14

Deadline information: Applications due by 5pm local time of applicant organisation.

Deadlines on: 5 May 2014, 5 September 2014, 5 January 2015, 5 May 2015, 4 September 2015, 5 January 2016, 5 May 2016, 4 September 2016, 5 January 2017.

Posted date: 22 Nov 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-007.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PAR-14-007>

Eligibility profile

Country of applicant institution: Any

Disciplines

Oncology Nursing, Brain Tumour, Nursing, Economics and Econometrics (RAE Unit 38), Breast Cancer, Hospital-based Clinical Subject, Physiology, Colorectal Cancer/Colon Cancer/Bowel Cancer, Ovarian Cancer, Nursing (RAE Unit 10), Skin Cancer, Computer Sciences, Physiology (RAE Unit 7), HIV Infection, Methodologies & Procedures (Health & Safety & Medical), Oncology, Blood Cancer, Transmission of HIV/AIDS, Feasibility Studies, Computer Science (RAE Unit 25), Hospital-based Clinical Subjects (RAE Unit 3), Anatomy (RAE Unit 6), Cancer & Carcinogenesis, Leukaemia, Lung Cancer, Economics, Data Analysis, Clinical Laboratory Sciences (RAE Unit 1), Cancer Care, Cancer Biology, AIDS, Tumour Immunology, Cancer Nanotechnology, Clinical Laboratory Science, Prostate Cancer, Anatomy

Contact Details

NCI
6120 Executive Boulevard
Bethesda, MD 20892-7150
Tel: +1 301 496 7800

NCI EXPLORATORY/DEVELOPMENTAL RESEARCH GRANT PROGRAMME (R21):
AIDS-RELATED
NIH: National Cancer Institute

Description:

The National Cancer Institute invites Aids-related applications for its exploratory/developmental research grant programme for cancer research (R21). This Aids-related R21 funding opportunity announcement supports the developmental of new research activities in all areas of cancer research. The mechanism is intended to encourage exploratory and developmental research projects by exploring support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models or applications that could have a major impact on a field of cancer research, either biomedical, behavioural or clinical.

Application budgets are limited to US\$275,000 over a two-year project period, with no more than US\$200,000 available in any year. PAR-13-146 (replaces PAR-12-145).

Closing date: 05 Sep 14

Deadline information: Proposals due by 5pm applicant's local time on 5 September 2013; 5 January, 5 May and 5 September 2014; 5 January, 5 May and 4 September 2015.

Posted date: 20 Mar 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-146.html>

Application form:

<http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm>

Eligibility profile

Country of applicant institution: Any

Disciplines

Transmission of HIV/AIDS, Economics, Feasibility Studies, Cancer Biology, AIDS, Breast Cancer, Cancer & Carcinogenesis, HIV Infection, Prostate Cancer, Tumour Immunology, Methodologies & Procedures (Health & Safety & Medical), Nursing, Oncology, Anatomy, Computer Sciences, Data Analysis, Clinical Laboratory Sciences (RAE Unit 1), Hospital-based Clinical Subjects (RAE Unit 3), Anatomy (RAE Unit 6), Physiology (RAE Unit 7), Nursing (RAE Unit 10), Computer Science (RAE Unit 25), Economics and Econometrics (RAE Unit 38), Cancer Care, Leukaemia, Clinical Laboratory Science, Brain Tumour, Oncology Nursing, Blood Cancer, Cancer Nanotechnology, Hospital-based Clinical Subject, Physiology, Lung Cancer, Ovarian Cancer, Colorectal Cancer/Colon Cancer/Bowel Cancer, Skin Cancer

Contact Details

National Cancer Institute
6116 Executive Boulevard
Suite 300
Bethesda MD 20892-8322



A IDS-SCIENCE TRACK AWARD FOR RESEARCH TRANSITION (R03) NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-science track award for research transition programme. This R03 funding opportunity announcement seeks to facilitate the entry of new and early-career investigators to the area of drug abuse research on HIV/Aids. To promote the entry of new investigators into research on the natural history, epidemiology, aetiology and pathogenesis, prevention and treatment of Aids in drug abusers, the FOA will support the following types of projects:

- pilot or feasibility studies;
- secondary analysis of existing data;
- small, self-contained research projects;
- development of research methodology;
- development of new research technology.

Applicants may request direct costs of up to US\$100,000 per year over a project duration of up to two years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-12-282 (replaces PAR-10-021).

Closing date: 07 Sep 14

Deadline information: Applications due by 5pm local time of applicant organisation.

Deadlines on: 7 September 2013, 7 September 2014, 7 September 2015.

Posted date: 11 Sep 12

Award type: Directed grants to institutions, research groups etc, Innovation grants

Award amount max: \$200,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-12-282.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFormFedgrants?opportunity=PA-12-282>

Eligibility profile

Country of applicant institution: Any

Disciplines

Drug & Substance Abuse, Transmission of HIV/AIDS, AIDS, HIV Infection, Disease Prevention, Preventive Medicine, Treatment, Medical, Aetiology, Natural History of Disease, Pathogenesis, Epidemiology, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Clinical Laboratory Science, Community-based Clinical Subjects

Contact Details

Division of Clinical Neuroscience and Behavioural Research
National Institute on Drug Abuse
NIH/DHHS
6001 Executive Boulevard
Room 3152, MSC 9593
Bethesda, MD 20892-9593
Tel: +1 301 443 3207
Fax: +1 301 443 6814
Email: aklinwm@mail.nih.gov

S **MALL GRANTS FOR NEW INVESTIGATORS TO PROMOTE DIVERSITY IN HEALTH-RELATED RESEARCH (R03): AIDS-RELATED**
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:

The National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Mental Health and the Office of Dietary Supplements invite applications for Aids-related small grants for new investigators to promote diversity in health-related research (R03). This Aids-related R03 funding opportunity announcement will provide support for new investigators from underrepresented backgrounds to conduct small research projects in the areas of research relevant to the sponsoring institutes. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is intended to support small research projects that can be carried out in a short period of time with limited resources.

Direct costs are limited to US\$125,000 per year for a maximum of three years. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PAR-13-074 (replaces PAR-09-223).

Closing date: 07 Sep 14

Deadline information: Applications due annually on 7 September until 8 September 2015. Deadlines on: 7 September 2013, 7 September 2014, 7 September 2015.

Posted date: 08 Jan 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$375,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-074.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-074>

Eligibility profile

Country of applicant institution: Any

Disciplines

Nutrition & Dietetics, AIDS, Diabetes, Digestive Diseases & Disorders, HIV Infection, Kidney Disease, Obesity, Metabolism, Endocrinology, Haematology, Urology, Clinical Laboratory Sciences (RAE Unit 1), Hospital-based Clinical Subjects (RAE Unit 3), Clinical Laboratory Science, Hospital-based Clinical Subject

Contact Details

Office of Minority Health Research Coordination

NIDDK

6707 Democracy Boulevard
II Democracy Plaza, Room 906-B,
MSC 5454

Bethesda, MD 20892-5454

Tel: +1 301 594 9652

Email: mcbrydekd@mail.nih.gov

S YNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETERIOUS EFFECTS (R03): AIDS-RELATED NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-related call on synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R03). This Aids-related R03 funding opportunity announcement aims to deepen knowledge of the use of synthetic psychoactive drugs, their mechanisms of action and their health effects, as well as develop prevention strategies and treatment strategies.

This FOA uses the R03 small grant programme grant mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-105 and PA-14-106 which use the R21 exploratory/developmental and R01 research project grant mechanisms respectively.

The combined budget for direct costs for the maximum two year project period may not exceed US\$100,000. No more than US\$50,000 in direct costs may be requested in any single year.

Applications may be submitted by foreign or US for-profit and non-profit organisations and public and private organisations.

Ref: PA-14-014.

Closing date: 07 Sep 14

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 21 Feb 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-104.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PA-14-104>

Eligibility profile

Country of applicant institution: Any

Disciplines

Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Drug-Receptor Interaction, Hospital-based Clinical Subjects (RAE Unit 3), Transmission of HIV/AIDS, Drug Design, Drug Metabolism, Behaviour & Health, Chemistry (RAE Unit 18), Methods of Drug Delivery, Treatment, Medical, Hospital-based Clinical Subject, Drug & Substance Abuse, Community-based Clinical Subjects, Psychology (RAE Unit 13), HIV Infection, Clinical Laboratory Science, AIDS

Contact Details

Tel: +1 301 435 1304

Email: rrapaka@nida.nih.gov

SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETERIOUS EFFECTS (R21): AIDS-RELATED NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-related call on synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R21). This Aids-related R21 funding opportunity announcement aims to deepen knowledge of the use of synthetic psychoactive drugs, their mechanisms of action and their health effects, as well as develop prevention strategies and treatment strategies.

This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-104 and PA-14-106 which use the R03 small grant and R01 research project grant mechanisms respectively.

The combined budget for direct costs for the maximum two year project period may not exceed US\$275,000. No more than US\$200,000 may be requested in any single year.

Applications may be submitted by foreign or US for-profit and non-profit organisations and public and private organisations.

Ref: PA-14-105.

Closing date: 07 Sep 14

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 21 Feb 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-105.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PA-14-105>

Eligibility profile

Country of applicant institution: Any

Disciplines

Treatment, Medical, Chemistry (RAE Unit 18), Drug & Substance Abuse, Community-based Clinical Subjects, Hospital-based Clinical Subjects (RAE Unit 3), Drug Design, Behaviour & Health, AIDS, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Drug-Receptor Interaction, Psychology (RAE Unit 13), HIV Infection, Clinical Laboratory Science, Methods of Drug Delivery, Hospital-based Clinical Subject, Transmission of HIV/AIDS, Drug Metabolism

Contact Details

Tel: +1 301 435 1304

Email: rrapaka@nida.nih.gov

FAMILY-CENTRED SELF-MANAGEMENT OF CHRONIC CONDITIONS (R21): AIDS-RELATED *NIH: National Institute of Nursing Research*

Description:

The National Institute of Nursing Research invites applications for its Aids-related call on family-centred self-management of chronic conditions (R21). This Aids-related R21 funding opportunity announcement seeks to build on the science of family-centred self-management in chronic conditions.

This FOA uses the R21 exploratory/developmental research grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-112, which uses the R01 research project grant mechanism.

Foreign or US for-profit and non-profit organisations and public and private organisations may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PA-14-113.

Closing date: 07 Sep 14

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 25 Feb 14

Award type: Directed grants to institutions, research groups etc

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-113.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Social Policy and Administration (RAE Unit 40), Community-based Clinical Subjects (RAE Unit 2), AIDS, Transmission of HIV/AIDS, Chronic Diseases, Community-based Clinical Subjects, Outpatient, Community & Outreach Programmes, HIV Infection

Contact Details

Tel: +1 301 594 5970

Email: hussk@mail.nih.gov

ALCOHOL-INDUCED EFFECTS ON TISSUE INJURY AND REPAIR (R21): AIDS-RELATED *NIH: National Institute on Alcohol Abuse and Alcoholism*

Description:

The National Institute on Alcohol Abuse and Alcoholism invites Aids-related applications for its alcohol-induced effects on tissue injury and repair (R21) grants. This Aids-related R21 funding opportunity announcement supports the study of molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. The

NIAAA is especially interested in integrative research that elucidates alcohol's effects on complex mechanisms of injury and repair that are either common or specific to each organ system. The call also encourages the study of alcohol's effect on stem cells, embryonic development and regeneration, as well as the studies on molecular and cellular actions of moderate alcohol consumption.

This FOA will use the NIH R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-123, which solicits applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Direct costs are limited to US\$275,000 over a two-year period, with no more than US\$200,000 in direct costs allowed in any single year.

Ref:PA-14-124.

Closing date: 07 Sep 14

Deadline information: Applications due by 5pm, local time of applicant organisation, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 03 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-124.html>

Application form:

<http://www.grants.gov/web/grants/applicant/download-application-package.html#download=true&oppNum=PA-14-124>

Eligibility profile

Country of applicant institution: Any

Disciplines

Trauma, Cell Biology, Stem Cells, HIV Infection, Alcohol & Alcoholism, Clinical Laboratory Science, Injury, Biological Sciences (RAE Unit 14), Organs, AIDS, Cellular Pathology, Regeneration, Clinical Laboratory Sciences (RAE Unit 1), Embryology, Transmission of HIV/AIDS

Contact Details

Tel: +1 301 443 7351

Email: duntyw@mail.nih.gov



PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R34): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-related grants on the prevention and treatment of substance using populations with or at risk for hepatitis C virus (R34). This Aids-related R34 funding opportunity announcement encourages research focused on the prevention and treatment of hepatitis C virus to reduce new infections and identify and treat existing infections more effectively. This FOA supports the initial development of a clinical trial or research project focused on HCV for

at-risk substance using populations, including those with or at risk for HIV.

This FOA uses the R34 planning grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PA-14-136 and PA-14-137, which use the R21 exploratory/developmental grant mechanism and the R01 research project grant mechanisms respectively.

The combined budget for direct costs for the maximum three year project period may not

exceed US\$450,000. No more than US\$225,000 may be requested in any single year.

Applications may be submitted by foreign or US for-profit and non-profit organisations and public and private organisations.

Ref: PA-14-135.

Closing date: 07 Sep 14

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 04 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$450,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-135.html>

Application form:

<http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PA-14-135>

Eligibility profile

Country of applicant institution: Any

Disciplines

Clinical Laboratory Sciences (RAE Unit 1), HIV/AIDS, Social Aspects, Clinical Trial, Community-based Clinical Subjects (RAE Unit 2), HIV Infection, Clinical Laboratory Science, Treatment, Medical, Hepatic Disease, Drug & Substance Abuse, Community-based Clinical Subjects, Infectious Diseases & Agents, Transmission of HIV/AIDS, Disease Prevention

Contact Details

NIDA
6001 Executive Boulevard
Bethesda, MD 20892
Tel: +1 301 443 3207
Email: aklinwm@nida.nih.gov

PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R21): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-related grants on the prevention and treatment of substance using populations with or at risk for hepatitis C virus (R21). This Aids-related R21 funding opportunity announcement encourages research focused on the prevention and treatment of hepatitis C virus to reduce new infections and identify and treat existing infections more effectively. This FOA supports the initial development of a clinical trial or research project focused on HCV for at-risk substance using populations, including those with or at risk for HIV.

This FOA uses the R21 exploratory/developmental grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PA-14-135 and PA-14-137, which use the R34 planning grant mechanism and the R01 research project grant mechanisms respectively.

The combined budget for direct costs for the maximum two year project period may not exceed US\$275,000. No more than US\$200,000 may be requested in any single year.

Applications may be submitted by foreign or US for-profit and non-profit organisations and public and private organisations.

Ref: PA-14-136.

Closing date: 07 Sep 14

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 04 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-136.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-136>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/AIDS, Social Aspects, Clinical Trial, Community-based Clinical Subjects (RAE Unit 2), HIV Infection, Clinical Laboratory Science, Treatment, Medical, Hepatic Disease, Drug & Substance Abuse, Community-based Clinical Subjects, Infectious Diseases & Agents, Transmission of HIV/AIDS, Disease Prevention, Clinical Laboratory Sciences (RAE Unit 1), AIDS

Contact Details

NIDA

6001 Executive Boulevard

Bethesda, MD 20892

Tel: +1 301 443 3207

Email: aklinwm@nida.nih.gov

NEUROIMMUNE MECHANISMS OF ALCOHOL-RELATED DISORDERS (R21): AIDS-RELATED NIH: National Institute on Alcohol Abuse and Alcoholism

Description:

The National Institute on Alcohol Abuse and Alcoholism invites Aids-related applications for its grants on neuroimmune mechanisms of alcohol-related disorders (R21). This Aids-related R21 funding opportunity announcement seeks studies to address the role of neuroimmune modulation in response to and in the neuroadaptation of the brain to acute and chronic alcohol exposure, and alcohol dependence and withdrawal. The goal is to achieve fundamental insights of neuroimmune mechanisms underlying brain functional and behavioural changes induced by alcohol.

This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with an FOA of identical

scientific scope, PA-14-139 which uses the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Direct costs are limited to US\$275,000 over a two-year period, with no more than US\$200,000 in direct costs allowed in any single year.

Ref: PA-14-138.

Closing date: 07 Sep 14

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 04 Mar 14

Award type: Directed grants to institutions, research groups etc

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-138.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-138>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/AIDS, Social Aspects, Clinical Laboratory Sciences (RAE Unit 1), Alcohol &

Alcoholism, HIV Infection, Neuropsychology, Clinical Laboratory Science, Neurological Disorders, Psychology (RAE Unit 13), Biological Sciences (RAE Unit 14), Neurology, Neuroscience, Hospital-based Clinical Subject, Biology, Behavioural, Immunology, Behaviour & Health, Hospital-based Clinical Subjects (RAE Unit 3), Neurobiology, Transmission of HIV/AIDS, Neuroendocrinology, AIDS

Contact Details

NIAAA
5635 Fishers Lane
Rockville, MD 20852
Tel: +1 301 443 1678
Email: changhai.cui@nih.gov

COMMUNITY PARTNERSHIPS TO ADVANCE RESEARCH (R21): AIDS-RELATED

NIH: National Institute of Nursing Research

Description:

The National Institute of Nursing Research invites Aids-related applications for its community partnerships to advance research (R21). This Aids-related R21 funding opportunity announcement encourages researchers to partner with communities using community engaged research methodologies that will enhance relationships leading to better interventions and positive health outcomes.

This funding opportunity announcement will use the NIH R21 exploratory/developmental research grant award mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-142, which solicits applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are limited to US\$275,000 over a two-year project period, with no more than US\$200,000 in any year.

Ref: PAR-14-141.

Closing date: 07 Sep 14

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 05 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-141.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-141>

Eligibility profile

Country of applicant institution: Any

Disciplines

Hospital-based Clinical Subjects (RAE Unit 3), Transmission of HIV/AIDS, Nursing (RAE Unit 10), Intervention, Agents for (Health & Safety & Medical), Hospital-based Clinical Subject, Patient Outcomes, Community-based Clinical Subjects (RAE Unit 2), Community-based Clinical Subjects, Intervention, Types of (Health & Safety & Medical), Translational

Medicine, Nursing, HIV/AIDS, Social Aspects, HIV Infection, Methodologies & Procedures (Health & Safety & Medical), AIDS

Contact Details

NINR
National Institutes of Health
31 Center Drive, Room 5B10
Bethesda MD 20892-2178
Tel: +1 301 594 5971
Email: mccloskd@mail.nih.gov

ESTABLISHING BEHAVIOURAL AND SOCIAL MEASURES FOR CAUSAL PATHWAY RESEARCH IN DENTAL, ORAL AND CRANIOFACIAL HEALTH (R21): AIDS-RELATED

NIH: National Institute of Dental and Craniofacial Research

Description:

The National Institute of Dental and Craniofacial Research invites Aids-related applications for its grants on establishing behavioural and social measures for causal pathway research in dental, oral and craniofacial health (R21). This Aids-related R21 funding opportunity announcement aims to establish measures of specific behavioural or social phenomena to test causal hypotheses about behavioural and social contributors to dental, oral or craniofacial diseases. This announcement encourages the development and testing of two types of measures:

- measures of the health behaviours, social interactions, community characteristics, built environments, targeted by behavioural or social interventions to improve oral health;
- measures of the hypothesised moderators and mediators of a behavioural or social intervention's effect.

This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with an FOA of identical

scientific scope, PAR-14-143, which uses the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions may apply.

Application budgets are limited to US\$275,000 over a two-year project period, with no more than US\$200,000 in any year.

Ref: PAR-14-144.

Closing date: 07 Sep 14

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 06 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-144.html>

Application form:

<http://www.grants.gov/web/grants/applicant>

[s/download-application-package.html#download=true&oppNum=PAR-14-144](#)

Eligibility profile

Country of applicant institution: Any

Disciplines

Oral Medicine, Transmission of HIV/AIDS, Dental Diagnostic Sciences, Oral Pathology, Paediatric Dentistry, Craniofacial Diseases and Disorders, Community-based Clinical Subjects, Dental Health & Hygiene, Oral Diseases, Dental Health Education, Psychology (RAE Unit 13), Restorative

Dentistry, Dental Health Sciences, HIV Infection, Dentistry, Clinical Dentistry (RAE Unit 4), AIDS, Basic Dental Sciences, Oral and Maxillofacial Surgery, Community-based Clinical Subjects (RAE Unit 2), Dental Special Needs, HIV/AIDS, Social Aspects, Preventive Dentistry, Behaviour & Health

Contact Details

NIDCR
6701 Democracy Boulevard
Bethesda, MD 20817
Tel: +1 301 451 3888
Email: riddleme@mail.nih.gov

T TRANSLATIONAL RESEARCH TO HELP OLDER ADULTS MAINTAIN THEIR HEALTH AND INDEPENDENCE IN THE COMMUNITY (R21): AIDS-RELATED *NIH: National Institute on Aging*

Description:

The National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering invite applications for their Aids-related call on translational research to help older adults maintain their health and independence in the community (R21). This Aids-related R21 funding opportunity announcement supports translational research collaborations between academic research centres and community-based organisations with expertise in serving or engaging older adults to develop tools, techniques, programmes or policies to respond to the needs of the ageing population.

This FOA uses the R21 exploratory/developmental research grant award mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-161, which solicits applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are limited to US\$275,000 over a two-year project period, with no more than US\$200,000 in any year.
Ref: PAR-14-159 (replaces PAR-11-124).

Closing date: 07 Sep 14

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 21 Mar 14

Award type: Networking/collaboration, Directed grants to institutions, research groups etc
Award amount max: £275,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-159.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true?oppNum=PA-14-159>

Eligibility profile

Country of applicant institution: Any

Disciplines

Community-based Clinical Subjects (RAE Unit 2), Psychology of Ageing, HIV/AIDS, Social Aspects, Access to Health Care, AIDS,

Independent Living, Ageing & Gerontology, Psychology (RAE Unit 13), Social Policy and Administration (RAE Unit 40), Community-based Clinical Subjects, Community & Outreach Programmes, Health Planning & Policy, Transmission of HIV/AIDS, Home Health Care Services

Contact Details

NIA
7201 Wisconsin Avenue
Bethesda, MD 20814
Tel: +1 301 402 4156
Email: kingjo@nia.nih.gov



EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN
(R21): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-related call on the effects of cannabis use and cannabinoids on the developing brain (R21). This Aids-related R21 funding opportunity announcement supports the study of effects and functional consequences of cannabis and cannabinoid exposures on the developing brain, from pre-, peri- and postnatal development through young adulthood in animal models and humans.

This FOA uses the R21 exploratory/developmental grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PA-14-163 and PA-14-164, which use the R01 research project grant mechanism and the R03 small research grant mechanism respectively.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.

Direct costs are limited to US\$275,000 over a two-year project period, with no more than US\$200,000 in any year.
Ref: PA-14-162.

Closing date: 07 Sep 14

Deadline information: Applications due by 5pm proposer's local time every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 27 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-162.html>

Application form:

<http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true?oppNum=PA-14-162>

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/AIDS, Social Aspects, Community-based Clinical Subjects (RAE Unit 2), AIDS, Clinical Laboratory Sciences (RAE Unit 1), Cognitive Development & Processes, HIV Infection, Clinical Laboratory Science, Psychology (RAE Unit 13), Drug & Substance Abuse, Brain, Community-based Clinical Subjects,

Neurology, Neuroscience, Drug Metabolism, Transmission of HIV/AIDS

Contact Details

NIDA
6001 Executive Boulevard
Bethesda, MD 20892
Tel: +1 301 435 4649
Email: wudy@mail.nih.gov

EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R03): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:

The National Institute on Drug Abuse invites applications for its Aids-related call on the effects of cannabis use and cannabinoids on the developing brain (R03). This Aids-related R21 funding opportunity announcement supports the study of effects and functional consequences of cannabis and cannabinoid exposures on the developing brain, from pre-, peri- and postnatal development through young adulthood in animal models and humans.

This FOA uses the R03 small research grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PA-14-162 and PA-14-163, which use the R21 exploratory/developmental grant mechanism and the R01 research project grant mechanism respectively.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.

Direct costs are limited to US\$100,000 over a two-year project period, with no more than US\$50,000 in any year.

Ref: PA-14-164.

Closing date: 07 Sep 14

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 27 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: \$100,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PA-14-164.html>

Application form:

<http://www.grants.gov/web/grants/applicant/download-application-package.html#download=true?oppNum=PA-14-164>

Eligibility profile

Country of applicant institution: Any

Disciplines

Transmission of HIV/AIDS, Drug Metabolism, Brain, Drug & Substance Abuse, Neurology, Community-based Clinical Subjects, Neuroscience, Cognitive Development & Processes, HIV Infection, Clinical Laboratory Science, Psychology (RAE Unit 13), HIV/AIDS, Social Aspects, Community-based Clinical Subjects (RAE

Unit 2), AIDS, Clinical Laboratory Sciences
(RAE Unit 1)

6001 Executive Boulevard
Bethesda, MD 20892
Tel: +1 301 435 4649
Email: wudy@mail.nih.gov

Contact Details

NIDA



NIDA RESEARCH EDUCATION PROGRAMME FOR CLINICAL RESEARCHERS AND CLINICIANS (R25): AIDS-RELATED *NIH: National Institute on Drug Abuse*

Description:

The National Institute on Drug Abuse invites applications for its Aids-related research education programme for clinical researchers and clinicians (R25) grants. This R25 funding opportunity announcement will support research education for those in clinically focused careers, in a topic area related to substance use, abuse or addiction. Participants should be training for careers as clinical researchers, clinicians or service providers, or optimally a combination of the two. This mechanism may not be used to support non-related-related clinical training.

Direct costs are limited to US\$350,000 in direct costs allowed in any single year. The maximum project period is five years. Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. PAR-13-084 (replaces PAR-10-173).

Closing date: 08 Sep 14

Deadline information: Applications due by 5pm proposer's local time. Deadlines on: 9 September 2013, 8 September 2014, 7 September 2015.

Posted date: 11 Jan 13

Award type: Directed grants for individual investigators, Personal development

Award amount max: \$1,750,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-084.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-084>

Eligibility profile

Country of applicant institution: Any

Disciplines

Drug & Substance Abuse, AIDS, HIV Infection, Clinical Medicine, General, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Clinical Laboratory Science, Community-based Clinical Subjects, Hospital-based Clinical Subject

Contact Details

Behavioural and Integrative Treatment Branch

Division of Clinical Neuroscience and Behavioural Research

NIDA

6001 Executive Boulevard, Room 3157, MSC 9551

Bethesda, MD 20892-9551

Tel: +1 301 443 0107

Fax: +1 301 443 6814

Email: dg79a@nih.gov

NHLBI SYSTEMS BIOLOGY COLLABORATIONS (R01) *NIH: National Heart, Lung and Blood Institute*

Description:

The National Heart, Lung and Blood Institute invites grant applications for its systems biology collaborations (R01). This R01 funding opportunity announcement funds collaborative systems biology research projects by multi-disciplinary teams to advance understanding of normal physiology and perturbations associated with heart, lung, blood, and sleep diseases and disorders. Multi-disciplinary expertise across experimental and computational domains is required and the multi-PI mechanism is allowed, as integration across these domains is a critical element of the proposed research plan. The goal of this funding opportunity announcement is to improve our understanding of complex HLBS biological systems through the development of predictive mathematical models that make new testable predictions of how the biological system will respond to perturbations seen during development, adaptation, or disease. The mathematical model proposed in the application must recapitulate the known characteristics of a biological system and predict responses of the system to novel perturbations. While bioinformatic and statistical expertise may be essential components of research proposed under this FOA, applications must include predictive, mechanistic, quantitative models that generate testable hypotheses about the physiological and pathophysiological mechanisms that underlie the responses to perturbation.

Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. The maximum project period is five years. PAR-12-138 (replaces PAR-09-214).

Closing date: 15 Sep 14

Deadline information: Deadline: 14 September 2012; 14 January, 13 September 2013; 13 January, 15 September 2015.

Posted date: 26 Mar 12

Award type: Directed grants to institutions, research groups etc

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-12-138.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-138>

Eligibility profile

Country of applicant institution: Any

Disciplines

Heart, Respiratory System, Blood Diseases, Cardiovascular Diseases, Lung Disease, Sleep Disorders, Mathematical Model (Medical), Cardiology, Haematology, Clinical Laboratory Sciences (RAE Unit 1), Biological Sciences (RAE Unit 14), Applied Mathematics (RAE Unit 23), Systems Biology, Clinical Laboratory Science

Contact Details

Blood Disease Branch
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
NIH
6701 Rockledge Drive, MSC 7950
Bethesda, MD 20892-7940
Tel: +1 301 435 0050
Fax: +1 301 480 0867
Email: gasbap@nhlbi.nih.gov

B IOPHYSICAL AND BIOMECHANICAL ASPECTS OF EMBRYONIC DEVELOPMENT (R01) NIH: National Institute of Child Health and Human Development

Description:

The National Institute of Child Health and Human Development, the National Heart, Lung and Blood Institute and the National Institute of General Medical Sciences invites applications for their biophysical and biomechanical aspects of embryonic development (R01) grants. This R01 funding opportunity announcement seeks applications that propose to advance scientific knowledge in the area of the physics and mechanics of embryonic development. Applicants must propose hypothesis-driven developmental research with the prospect of gaining new and critical information about tissue mechanics relevant to vertebrate development and understanding the basis for developmental disorders. Investigators are encouraged to explore approaches and concepts new to the area of developmental tissue mechanics, and use newly developed techniques superior to the ones currently used in the field. Applications require sufficient preliminary data to substantiate the validity of the proposed research and feasibility of new technologies or tools.

This funding opportunity announcement will use the R01 research project grant mechanism, and runs in parallel with a FOA of identical scientific scope, PAR-13-206, which encourages applications under the R21 exploratory/developmental grant mechanism.

Direct costs are limited to US\$500,000 per year over a maximum five-year period. Eligible organisations include domestic and foreign for-profit and non-profit organisations and public or private institutions. PAR-13-207 (replaces PAR-10-221).

Closing date: 17 Sep 14

Deadline information: Applications due by 5pm local time of applicant organisation, 17 September annually until 18 September 2015.

Posted date: 18 Sep 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$2,500,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-207.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-207>

Eligibility profile

Country of applicant institution: Any

Disciplines

Child & Maternal Health, Physiological & Development Process, Paediatrics, Biological Sciences, Embryology, Human Development, Hospital-based Clinical Subjects (RAE Unit 3), Biological Sciences (RAE Unit 14), Hospital-based Clinical Subject

Contact Details

Developmental Biology and Structural Variation Branch
NICHD
6100 Executive Boulevard
Bethesda, MD 20892-7510
Tel: + 301 435 6886
Email: mukhopam@mail.nih.gov

B IOPHYSICAL AND BIOMECHANICAL ASPECTS OF EMBRYONIC DEVELOPMENT (R21) NIH: National Institute of Child Health and Human Development

Description:

The National Institute of Child Health and Human Development and the National Heart, Lung and Blood Institute invites applications for their biophysical and biomechanical aspects of embryonic development (R21) grants. This R21 funding opportunity announcement will support innovative and high-risk or high-impact research in the area of physics/mechanics of embryonic development to be explored in model organisms. The research proposed under this programme can explore approaches and concepts new to the area of developmental tissue mechanics; research and development of new technologies; or initial research and development of data upon which significant future research may be built. The focus of this FOA is to promote research aimed at generating new and critical information about tissue mechanics relevant to vertebrate development and understanding the basis for developmental disorders. While minimal or no preliminary data are expected to be described, applications should clearly indicate the significance of the proposed work and that the proposed research or development is scientifically sound, that the qualifications of the investigators are appropriate, and that resources available to the investigators are adequate.

This funding opportunity announcement will use the R21 exploratory/developmental grant mechanism, and runs in parallel with a FOA of identical scientific scope, PAR-13-207, which encourages applications under the R01 research project grant mechanism. Direct costs are limited to US\$275,000 over an R21 two-year period, with no more than US\$200,000 in direct costs allowed in any single year. Eligible organisations include domestic and foreign for-profit and non-profit organisations

and public or private institutions. PAR-13-206 (replaces PAR-10-222).

Closing date: 17 Sep 14

Deadline information: Applications due by 5pm local time of applicant organisation, 17 September annually until 18 September 2015.

Posted date: 23 Apr 13

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-206.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-206>

Eligibility profile

Country of applicant institution: Any

Disciplines

Child & Maternal Health, Physiological & Development Process, Paediatrics, Biological Sciences, Embryology, Human Development, Hospital-based Clinical Subjects (RAE Unit 3), Biological Sciences (RAE Unit 14), Hospital-based Clinical Subject

Contact Details

Developmental Biology and Structural Variation Branch
NICHD
6100 Executive Boulevard
Bethesda, MD 20892-7510
Tel: + 301 435 6886
Email: mukhopam@mail.nih.gov

EARLY-STAGE INNOVATIVE MOLECULAR ANALYSIS TECHNOLOGY DEVELOPMENT FOR CANCER RESEARCH (R21) NIH: National Cancer Institute

Description:

The National Cancer Institute invites applications for its early-stage innovative molecular technology development for cancer research programme. This R21 funding opportunity announcement solicits grant applications proposing exploratory research projects focused on the inception and development of early-stage, highly innovative, technologies or emerging technologies with significant transformative potential that has not yet been explored in a cancer-relevant use. The emphasis of this FOA is on molecular analysis technologies with a high degree of technical innovation with the potential to significantly affect and transform investigations exploring the molecular and cellular bases of cancer. If successful, these technologies would accelerate or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be based on molecular or cellular characterisations of cancer.

This funding opportunity uses the R21 exploratory/developmental research grant mechanism and runs in parallel with three of related scientific scope, RFA-CA-14-004, RFA-CA-14-005, RFA-CA-14-006.

Direct costs are limited to US\$500,000 over an R21 three-year period, with no more than US\$200,000 in direct costs allowed in any single year. NCI intends to commit approximately US\$5 million in fiscal year 2015 to support up to 22 awards.

Domestic and foreign for-profit or non-profit organisations and public or private institutions are eligible to apply. Ref: RFA-CA-14-003 (replaces RFA-CA-13-001).

Closing date: 18 Sep 14

Deadline information: Applications due by 5pm, local time of applicant organisation.

Posted date: 23 Dec 13

Award type: Innovation grants, Directed grants to institutions, research groups etc

Award amount max: \$500,000

Website:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-14-003.html>

Application form:

<http://www.grants.gov/web/grants/applicant/download-application-package.html#download=true&oppNum=RFA-CA-14-003>

Eligibility profile

Country of applicant institution: Any

Disciplines

Clinical Laboratory Sciences (RAE Unit 1), Biochemistry, Instrumentation, Medical, Biotechnology, Medical Devices, Clinical Engineering, Biomedical Engineering, Medical and Biotechnology (Diagnostics), Intervention, Types of (Health & Safety & Medical), Biology, Cellular, Cancer & Carcinogenesis, Clinical Biochemistry, Biological Sciences (RAE Unit 14), Biological Sciences, Clinical Laboratory Science, Biology, Molecular, Instruments & Instrumentation & Devices (Health & Medical), Bioengineering, Biochemical Engineering, Instrumentation, Biological, Intervention, Agents for (Health & Safety & Medical), Cancer Biology

Contact Details

Center for Strategic Scientific Initiatives,
Office of the Director
National Cancer Institute
31 Center Drive, Room 10A-33

Bethesda, MD 20892
Tel: +1 301 547 9980

Email: dickherberaj@mail.nih.gov

D **ESIGN AND DEVELOPMENT OF NOVEL TECHNOLOGIES FOR HEALTHY INDEPENDENT LIVING (R21)**

NIH: National Institute of Biomedical Imaging and Bioengineering

Description:

A total of six institutes and offices of the National Institutes of Health invite applications for their design and development of novel technologies for healthy independent living (R21) grants. This R21 funding opportunity announcement supports the design and development of novel technologies to monitor health or deliver care in a real-time, accessible, effective and minimally obtrusive way. Systems may be novel sensor or monitoring systems, home-use point-of-care devices, home or mobile therapy or rehabilitation tools, or information systems. Systems should also have the goal of fostering healthy and independent living.

This funding opportunity announcement will use the NIH R21 exploratory/developmental research grant award mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-118, which solicits applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are limited to US\$275,000 over a two-year project period, with no more than US\$200,000 in any year.

Ref: PAR-14-119 (replaces PAR-11-021).

Closing date: 23 Sep 14

Deadline information: Applications due by 5pm proposer's local time. Deadlines on: 23 September 2014, 23 September 2015, 23 September 2016.

Posted date: 27 Feb 14

Award type: Innovation grants, Networking/collaboration

Award amount max: \$275,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-119.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Biosensors , Instrumentation, Biological, Clinical Laboratory Sciences (RAE Unit 1), Home Health Care Services, Technology Transfer, Biotechnology, Biological Sciences (RAE Unit 14), Health Services Delivery, Technological Aids for Disabled People, Clinical Laboratory Science, Health Care Options, Outpatient, Technology Assessment

Contact Details

NIBIB

Tel: +1 301 402 1337

Email: rodgersmm@mail.nih.gov

TECHNOLOGIES FOR HEALTHY INDEPENDENT LIVING (R01) *NIH: National Institute of Biomedical Imaging and Bioengineering*

Description:

A total of six institutes and offices of the National Institutes of Health invite applications for their technologies for healthy independent living (R01) grants. This R01 funding opportunity announcement supports research and development of technologies to monitor and deliver healthcare in a real-time, accessible, effective and minimally obtrusive way. Systems should integrate, process, analyse communicate and present data in order to engage individuals and empower them in their own healthcare.

This funding opportunity announcement will use the NIH R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-119, which solicits applications under the R21 exploratory/developmental research grant award mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited but need to reflect actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-14-118 (replaces PAR-11-020).

Closing date: 23 Sep 14

Deadline information: Applications due by 5pm proposer's local time. Deadlines on: 23 September 2014, 23 September 2015, 23 September 2016.

Posted date: 27 Feb 14

Award type: Innovation grants, Directed grants to institutions, research groups etc

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-118.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Biotechnology, Clinical Laboratory Sciences (RAE Unit 1), Instrumentation, Biological, Technology Assessment, Health Care Options, Biosensors , Outpatient, Technological Aids for Disabled People, Health Services Delivery, Clinical Laboratory Science, Biological Sciences (RAE Unit 14), Technology Transfer, Home Health Care Services

Contact Details

NIBIB

Tel: +1 301 402 1337

Email: rodgersmm@mail.nih.gov

GENETIC AND GENOMIC ANALYSIS OF XENOPUS (R01) *NIH: National Institute of Child Health and Human Development*

Description:

The National Institute of Child Health and Human Development, the National Institute on Deafness and Other Communication Disorders and the National Institute of General Medical Sciences, in collaboration

with the trans-NIH xenopus working group, invite proposals for the genetic and genomic analysis of xenopus. This R01 funding opportunity announcement invites investigator-initiated applications designed to exploit the power of xenopus as a vertebrate

model for biomedical research. Applications may propose to develop new tools or genetic, genomic or proteomic resources of high priority to the xenopus community that will advance the detection and characterisation of genes, pathways and phenotypes of interest in development, organogenesis and in cell biological processes, such as cell division, signalling and migration. This FOA welcomes applications that utilise the recently developed tools or resources to advance these goals, particularly when these projects employ tools that have not been previously used in xenopus research.

This FOA will utilise the NIH research project grant (R01) award mechanism and runs in parallel with an FOA of identical scientific scope, PAR-12-249, which encourages applications under the NIH exploratory/developmental (R21) grant mechanism. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Applications will be accepted from domestic and foreign for-profit or non-profit organisations and public or private institutions. PAR-12-250 (replaces PAR-09-240)

Closing date: 30 Sep 14
Deadline information: Applications due by 5pm local time of applicant organisation.
Posted date: 26 Jul 12

Award type: Directed grants to institutions, research groups etc

Website:
<http://grants.nih.gov/grants/guide/pa-files/PAR-12-250.html>

Application form:
<http://grants.nih.gov/grants/guide/pa-files/PAR-12-250.html>

Eligibility profile

Country of applicant institution: Any

Disciplines

Disease Model, Gene Expression, Gene Regulation, Biology, Cellular, Cell Migration, Human Development, Molecular Genetics, Mutagenics, Biochemistry, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Biological Sciences (RAE Unit 14), Genomics, Clinical Laboratory Science, Community-based Clinical Subjects, Screening For Diseases

Contact Details

Developmental Biology and Teratology Branch
NICHD
6100 Executive Boulevard, Room 4B01B
Bethesda, MD 20892-7510
Tel: +1 301 451 1390
Fax: +1 301 480 0303
Email: coulombej@mail.nih.gov

GENETIC AND GENOMIC ANALYSIS OF XENOPUS (R21) *NIH: National Institute of Child Health and Human Development*

Description:

The National Institute of Child Health and Human Development and the National Institute on Deafness and Other Communication Disorders, in collaboration with the trans-NIH xenopus working group,

invite proposals for the genetic and genomic analysis of xenopus. This R21 funding opportunity announcement invites investigator-initiated applications designed to exploit the power of xenopus as a vertebrate model for biomedical research. Applications

may propose to develop new tools or genetic, genomic or proteomic resources of high priority to the xenopus community that will advance the detection and characterisation of genes, pathways and phenotypes of interest in development, organogenesis and in cell biological processes, such as cell division, signalling and migration. This FOA welcomes applications that utilise the recently developed tools or resources to advance these goals, particularly when these projects employ tools that have not been previously used in xenopus research.

This FOA will utilise the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-12-250, which encourages applications under the NIH research project grant (R01) mechanism. Direct costs are limited to US\$275,000 over an R21 two-year period. Applications will be accepted from domestic and foreign for-profit or non-profit organisations and public or private institutions. PAR-12-249 (replaces PAR-09-241).

Closing date: 30 Sep 14

Deadline information: Applications due by 5pm local time of applicant organisation. Deadlines on: 1 October 2012, 30 September 2013, 30 September 2014.

Posted date: 26 Jul 12

Award type: Directed grants to institutions, research groups etc

Award amount max: \$275,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-12-249.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-249>

Eligibility profile

Country of applicant institution: Any

Disciplines

Disease Model, Gene Expression, Gene Regulation, Biology, Cellular, Cell Migration, Human Development, Molecular Genetics, Mutagenics, Biochemistry, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Biological Sciences (RAE Unit 14), Genomics, Clinical Laboratory Science, Community-based Clinical Subjects, Screening For Diseases

Contact Details

Developmental Biology and Teratology Branch
NICHD
6100 Executive Boulevard, Room 4B01B
Bethesda, MD 20892-7510
Tel: +1 301 451 1390
Fax: +1 301 480 0303
Email: coulombej@mail.nih.gov

